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Osteoblast activities include bone formation, osteoclast regulation, and 
the secretion of a class of hormones called cytokines. Osteoblast-derived 
cytokines include Interleukin-6 (IL-6) and two colony stimulating factors 
(CSFs): Granulocyte-Macrophage CSF (GM-CSF), and Macrophage-CSF 
(M-CSF). Osteoblasts secrete cytokines after exposure to several well- 
characterized mitogens such as lipopolysaccharide (LPS), 
phytohemagglutinin (PHA), and Interleukin-1. What roles osteoblast- 
derived cytokines play in normal bone remodeling is unknown. 
Transforming Growth Factor-Beta (TGF-B) is a ubiquitous 23-25 kDa 
homodimeric protein stored in platelets and bone. TGF-B was originally 
discovered as an inducer of neoplastic transformation in normal fibroblasts 
but has since been implicated in matrix homeostasis, immunomodulation, 
development and hematopoesis. Bone is the body's largest source of TGF- 
B and the protein becomes activated after osteoclast bone resorption. No 
definitive role for TGF-B in bone remodeling is known. 
This thesis presents experiments which tested the effect of TGF-B on 
osteoblast cytokine production and release. Data from in vitro cytokine 
assays of conditoned media suggest that TGF-B upregulates IL-6 and GM- 
CSF secretion through a novel synergistic interaction with other low 
concentration molecules including LPS, IL-1, and parathyroid hormone 
(PTH), as a group referred to here as synergens. M-CSF secretion was 
unaffected by TGF-B alone or in combination with any synergen. 90% of 
the GM-CSF and IL-6 release observed is achieved between 2.5 and 6 
hours after exposure to TGF-B and a given synergen. Furthermore, the 
synergy between TGF-B and a given molecule is TGF-B-dependent. The 

osteoblast response was not altered by exposure to indomethacin. RNA 
analysis suggested that the synergy between TGF-6 and IL-1 may involve 
TGF-6 upregulation of the IL-1 cell surface receptor. These observations 
are the first to implicate TGF-B as a stimulatory molecule for cytokine 
release from osteoblasts and suggest new aspects of bone remodeling as 
well as a possible role for the osteoblast in hematopoesis. 

II. INTRODUCTION Growth factors and essential principles; 
The Discovery of Transforming Growth Factor-B; Osteoblast-derived cytokines; 
Thesis investigation. 
Throughout the life of the normal cell, there exists a tightly 
controlled series of programs designed to insure the orderly and 
regulatable growth and proliferation of the cell. These controls 
have enabled cells to survive the environmental fluctuations 
throughout evolution and everyday life: Cells survive starvation by 
slowing growth to minimal levels and cells maximize growth in 
environments consistent with growth. At any given moment, a cell 
must be aware of both its internal state as well as the external world. 
Without normal growth and proliferation controls, there can be dire 
consequences: An inability to respond appropriately to favourable 
environmental stimuli could result in decreased cell growth and 
premature senescence. Alternatively, an inability to check growth 
and to maintain quiescence, could result in inappropriate, sustained, 
and non-suppressable growth, an extreme condition known as cancer. 
Understanding how normal cells control the transitions 
between the states of quiescence and growth is paramount towards 
understanding why certain cells, i.e. neoplastic cells, cannot control 
these transitions (Figure II.i). The evolution of multicellular life 
presented a particular problem for cellular growth. Multicellular 
organisms required each cell to regulate growth in a manner 
appropriate to the growth of surrounding cells. How cells 
communicate to ensure such regulation is exceedingly complex and 
has intrigued investigators for at least 70 years. In 1916, Australian 
Brailsford Robertson (Figure II.ii) discovered that a murine 

pituitary extract stimulated the growth of juvenile mice. Robertson 
purified a substance capable of achieving the same effect, a substance 
4 
Figure ILi. Normal and abnormal cellular growth pathways. When presented with 
an environment devoid of growth signals normal cells respond by entering the 
quiescent state of Go (a). Neoplastic cells, however, may continue to proliferate 
irregularly (b). An environment replete with growth signals may induce normal 
cells to divide regularly (c), whereas abnormal cells may either grow unchecked as 
a neoplasia (di) or cease growth and enter Go (d2). 
he called tethelin.^ At the same time, J. M. Byrne and Eric 
Horning of Melbourne, Australia were attempting to grow 
mammalian cells in vitro using tissue extracts from normal and 
neoplastic tissue82. In 1929, after Byrne and Homing published 
their findings in the Australian Journal of Science, Robertson eagerly 
sent Byme and Homing samples of tethelin to test on their in vitro 
cultures. Working with chick enterocytes, cells cultured in the 
presence of tethelin grew faster than enterocytes cultured in chick 
plasma alone22. The significance of tethelin and tissue extracts 
towards the growth of cells was immediately appreciated and tethelin 
was accepted as the first 'growth factor' determined through in vitro 

analysis. The daunting task had only begun, however, in 
determining what specifically a ’growth factor' was, how growth 
factors worked, and what role(s) the factors played in normal in vivo 
physiology. 
Upon Robertson's death in 1929 and Homing's departure from 
Australia shortly thereafter these early efforts unfortunately came to 
a halt. In 1951, growth factor work eventually resumed when Rita 
Levi-Montalcini and Stanley Cohen (figure II.ii) isolated nerve 
growth factor (NGF) and epidermal growth factor (EGF)45T26 
The characterization of these two molecules spawned a renewed and 
intense effort to understand growth factor biology and growth factor 
Figure Il.ii. Pioneers in growth factor research. Australian T. Brailsford Robertson 
(1884-1930), left, isolated the first 'growth factor' from mouse pituitaries which he 
called tethelin (Greekr’growing') a molecule whose identity is still undetermined. 
Rita Levi-Montalcini (bom 1909), top right, and Stanley Cohen (born 1922), 
bottom right, both received Nobel prizes for medicine in 1986 for their work on 
Nerve Growth Factor and Epidermal Growth Factor, respectively, the first two 
Nobel laureates in the growth factor field. 

roles in physiology, guided by the ultimate goal of utilizing in vivo 
growth factor capabilities for clinical needs. By 1963, several new 
growth factors were isolated including Fibroblast Growth Factor 
(FGF), Platelet-Derived Growth Factor (PDGF) and Insulin-like 
Growth Factors 1 and 2 (IGFs-1 and -2). In 1972, Gery et al. 
isolated Lymphocyte Activating Factor (LAF) derived from 
macrophages67,68< Because LAF was derived from a type of white 
cell, and functioned as a growth mediator between white cells, LAF 
was eventually known as interleukin-l, or IL-1. IL-1 stimulated 
great interest not only because its potent T-cell stimulatory ability 
seemed immunologically relevant, but because IL-1 had other 
functions not directly leading to the 'usual' processes of growth, such 
as mitosis or proliferation. IL-1 was, for example, observed to 
stimulate cartilage resorption98, induce the intrinsic pathway of the 
clotting cascade128, chemoattract acute phase cells100, and cause 
profound fever1 T24. Furthermore, IL-1 induced T-cell growth by 
inducing the synthesis of interleukin-2, or IL-2, originally known as 
T-cell Growth Factor (TCGF)124. It appeared that certain growth 
factors had diverse roles in homeostasis and disease states. With 
attention shifted to the immune system, many growth factors were 
characterized which appeared to be specifically active in the growth 
and activity of immune cells. Molecules like Interleukin-2 were 
joined with six other interleukins (interleukins-3 through 8) and the 
Colony Stimulating Factors or CSFs: Granulocyte-Monocyte CSF 
(GM-CSF), Granulocyte-CSF (G-CSF), and Macrophage-CSF (M- 
C’SF). Thus, a new class of growth factors were found which 
promoted changes in cellular activity in addition to stimulating 

growth. These factors became broadly known as cytokines. 
Investigators soon demonstrated that cytokines could not be limited 
by activity or in source to cells of the immune system but could be 
isolated from cells as diverse as astrocytesI32b? kidney epithelial 
cells1370, endometrium154’!67b? and cells 0f bone87. The roles 
cytokines play in these and other systems is not definitively known. 
Growth factor research was made even more intriguing with the 
discovery of cytokines important to excessive growth and frank 
neoplastic change. Such molecules include the Transforming Growth 
Factors Alpha and Beta (TGF-a & TGF-B)5’62’166- These molecules 
were orginally observed in 1983 to induce neoplastic transformation 
in normal fibroblasts growing in soft agar. Transforming Growth 
Factors have generated great interest because of their possible role in 
wound repair, tissue differentiation and matrix formation. 
Transforming Growth Factor-6 (TGF-6) is decidedly unique 
among cytokines, however, in that it has been generally regarded as 
an inhibitory molecule of normal cells, often implicated in the 
suppression of normal growth. 
For example, Transforming Growth Factor-6 is 10,000- 
100,000 times as immunosuppressive as cyclosporin-A9. TGF-6 is 
ubiquitous, is stored primarily in the matrix of bone and is active 
only after release from binding proteins28’35,167,183 Bone is the 
richest source of TGF-6 in the body34,35 but no clear role is yet 
defined for TGF-6 in bone tissue biology. TGF-6 is now being 
tested in clinical trials as an immunosuppressive adjuvant in 
chemotherapy, and as a topical agent in wound healing9,167,183a# 
The obvious importance of this molecule for clinical pursuits 

necessitates a clear understanding of TGF-B’s actions in normal and 
abnormal human physiology. 
Figure Il.iii. Original observations for the existence of transforming growth 
factors, (a) Supernatants from neoplastic fibroblasts were aspirated and (b) added 
to cultures of normal fibroblasts in vitro. The normal fibroblasts, in turn, were 
observed to undergo transformation (c) and assume the neoplastic phenotype of the 
originally transformed cultures4. 
As mentioned above, cytokines are made by diverse populations 
of cells. Perhaps few cells in the body are as active in this regard as 
the osteoblast, the cell that forms bone. Evidence of cytokine 
production by bone cells is well-established, but the roles cytokines 
play in bone metabolism and bone resorption is unknown37^. 
Recalling that TGF-B is stored in bone, is the body's largest source 
of the cytokine, and bone resorptive processes can activate TGF-B, 
one may question if there is a relationship between TGF-B and the 

release of cytokines from osteoblasts. This thesis investigates the 
ability of TGF-6 and other cytokines to modulate the release of the 
known osteoblast-derived cytokines. To focus the implications of the 
data presented in this work, short discussions of the cells, cytokines 
and genes relevent to the interpretation of the data will be presented 
as follows. 
A. TRANSFORMING GROWTH FACTOR- BETA TGF-6 can 
transform 'primed' cells; TGF-6 is produced ubiquitously and stored in bone; 
There are multiple types of TGF-6s but TGF-61 is studied in the present work; 
TGF-6 is normally latent but is activated by low/ high pH and specific enzymes. 
It has long been conjectured that normal cells influence their own 
growth by releasing particular autocrine hormones which, in turn, 
stimulate the cell itself, or in a paracrine fashion, stimulate 
neighboring cells. Cancer cells may support their growth, in part, 
by over producing or responding inappropriately to normal 
autocrine hormones. Such a hypothesis gained credence when it was 
observed that supernatants from certain retrovirally transformed 
cells could transform previously normal fibroblasts growing in soft 
agar (Figure Il.iii above)4’62’166. The supernatants, it was thought, 
contained molecules produced by the transformed cells, which 
stimulated the transformed cells' growth and induced transformation 
in healthy cells. 
The molecules were referred to as Transforming Growth Factors 
(TGFs), initiating much effort towards the isolation and 
characterization of the still-theoretical material. In 1983, several 
workers eventually isolated two disparate proteins which had 
conferred upon supernatants an ability to transform healthy 

cells133b, One of the proteins, TGF-Alpha (TGF-a) was found to be 
related to Epidermal Growth Factor (EGF) and had equal affinity 
for the EGF-receptor as did EGF itself. The second protein, TGF- 
Beta (TGF-B) was unrelated to EGF and was a ligand for its own 
Figure Il.iv. Growth factor induction of active growth cycles. Quiescent cells can 
be activated into active growth after certain 'priming' events, initiated by Platelet- 
derived Growth Factor (PDGF). Either Epidermal Growth Factor (EGF) or 
Transforming Growth Factor-alpha (TGF-a) can then induce a cell to enter the first 
part of Gi. Insulin-like Growth Factor-1 (IGF-1) continues the induction of a 
normal cycle of growth. Cells exposed to TGF-B, however, may enter cell cycles 
which are not soon terminated, but continue in the unchecked manner typical of 
neoplastic growth. 
receptor complex9!’ 167,183. As illustrated in figure Il.iv, it was 
found that cells could be transformed by the TGFs only after 
promotion by factors normally present in serum, primarily Platelet- 
Derived Growth Factor (PDGF), and Insulin-like Growth Factor-1 
(IGF-1). TGF-a could substitute for EGF because the molecules 

were ligands for the same receptor. Once a cell had been thus 
promoted, TGF-8 alone could induce transformation91. Workers 
have since found that TGF-a is produced only by certain neoplastic 
cells in vitro. TGF-6, however, is ubiquitous, produced by many 
normal cells, especially developing tissues and tissues undergoing 
repair. TGF-6 is present in high concentrations in platelets (1500 
molecules per cell)5»195 and in bone (>30 mg/kg)35,167? suggesting 
that the molecule is important to soft tissue wound healing and 
mineralized tissue remodeling. It is now appreciated that TGF-6 is 
an important molecule in normal growth processes and that an 
understanding of TGF-6 biology in vivo will have many implications 
for basic science and clinical medicine. A great deal of information 
concerning TGF-8 has been accumulated, a description of which is 
beyond the scope of this work. A summary of the major elements of 
TGF-6 biology relevent to the data presented in this thesis follows. 
TGF-6 is a homodimeric protein, linked by sulfide bonds, with 
a molecular weight of 23-25,000 Daltons. By 1985, it was realized 
that several TGFs-6 existed, differing in messenger RNA and amino 
acid length and source of isolation. The original TGF-8, and the one 
studied in this thesis, was referred to as TGF-81, isolated from 
human platelets195, where it is stored in alpha-type granules167. 
TGF-62 was isolated from porcine platelets and bovine bone. TGFs- 
63.5 have not yet been isolated, but tentative cDNAs for these 
putative proteins have been identified in oocyte gene libraries73,183, 
Depending on the TGF-8 subspecies, TGF-6 mRNAs range from 
1.5-6.5 kilobases, with a processed message of approximately 1200 

kilobases in length. The mRNAs are translated into 380-420 amino 
acid TGF-B precursors which is cleaved on both the amino end and 
the carboxyl end to yield a 180 a.a. product. All TGF-Bs are 
generally equivalent in activity, despite their structural differences 
and, therefore, this discussion will refer to them all as TGF-B, unless 
otherwise stated. TGF-B is active in many tissues, as will be 
described shortly, but only after it has been released from a protein 
complex known as TGF binding protein (TBP). As shown below in 
figure II.v, cleavage of the last 112 amino acids from the carboxyl 
end of the original protein produces a TGF-B homodimer. Cleavage 
of the first 29 amino acids from the remnant precursor produces a 
sulfide-linked dimer which in turn binds to the TGF-B. The two 
dimers are themselves covalently linked to a larger, 125-160 kDa 
'modulator' protein167. 
The roles of these proteins are not known, but Kanzaki et al. 
found that the binding protein was not necessary for the latency of 
TGF-B i. Kanzaki suggests that the protein functions as a mediator 
of targeting, supported by the observation that both the binding 
protein, and the precursor protein both have the so-called "RGD" 
sequence- a fibronectin/vitreonectin cellular recognition site 
established by an Arginine-Glycine-Aspartic Acid triplet101. 
TGF-B is released in its active form by low or high pH ( <4.0 or 
>8.5) or by in vitro chaiotropic agents124’128. TGF-B release in 
vivo is most likely to be achieved, therefore, in microenvironments 
capable of generating such pH gradients. One site may be that of 
healing wounds where platelet-derived TGF-B i could be activated by 

1 3 
Figure II.v. Cleavage forms of TGF-B. (A.) Two precursor molecules are cleaved 
at sites indicated by arrows producing mature TGF-B and a large dimer to which the 
dimer TGF-B is bound. A 125-160 kDa 'modulator protein' (mp) is, in turn, 
bound to the two dimers, but a true function for the modulator protein is still 
unknown. (B.) Free, mature TGF-B as a 75 kDa homodimer. (C.) Two TGF-B 
molecules bound covalendy by alpha2-microglobulin (a2m), a proposed 'scavenger' 
protein for TGF-B and other potent growth factors. 
macrophage-derived sialidases, endoglycosidases, and other 
protonogenic proteases which can establish extremely low, local pH 
gradients (<3.7). A particularly unique site is that of resorption 
lacunae in bone, where resident osteoclasts resorb bone by utilizing 
basolateral proton pumps which can lower lacunar pH to 
approximately 3.0. Since latent TGF-Bi is stored in bone, 
resorption can release many molecules of TGF-Bi directly into a 
resorption lacuna while the low pH of the lacuna functions to activate 
TGF-B itself152. These mechanisms of TGF-B activation could 
insure that a responsive cell will not be affected by TGF-B unless the 
molecule is activated, as in conditions of inflammation, wound 

healing, or bone resorption. This strategem insures that the potency 
of TGF-B will be made manifest only where and when such a 
molecule is neccessary. 
Confirming the importance of activated TGF-B to its autocrine 
and paracrine function are observations concerning a human lung 
carcinoma cell line, A549. A549 cells are some of the most active 
producers of latent forms of TGF-B and express many TGF-B 
receptors. Active TGF-B, however, when added to A549 cells in 
vitro, greatly inhibits cell growth, suggesting that A549 cells have 
lost some ability to activate the TGF-B that the cells themselves 
release199. A cell, apparently, like the A549 cell, which releases 
TGF-B and expresses receptors for the molecule, must also have 
activating mechanisms to utilize any of the autocrine capablities 
which TGF-B may confer. 
TGF-B may be important in controlling cell growth by 
regulating the activity of the retinoblastoma gene product, RB. The 
retinoblastoma gene product may function as a growth suppressor 
because loss of function of the RB gene can lead to oncogenesis. 
Reintroduction of the RB product into proliferating cells which do 
not produce such product slows growth. The activity of the RB 
product is thought to be regulated post-translationally via protein 
phosphorylation states: Underphosphorylated RB is associated with 
growth-arrest and Gi whereas phosphorylated RB is found in S 
phase and G2/M. TGF-B was found to inhibit RB phosphorylation. 
SV40 virus large T antigen binds the RB product and this large T 
antigen specifically inhibits the growth suppressive activity of TGF- 
B!20. 

Activated, processed TGF-B has been found to bind avidly to 
alpha2-microglobulin, the 240 kDa serum protein. Alpha2- 
microglobulin, or other TGF-B binding serum proteins, may be one 
of the physiologic 'scavenging' mechanisms whereby the availability 
of activated TGF-6 is regulated (Figure II.v)198. TGF-B acts as a 
ligand for two glycoprotein membrane-bound receptors and one 
betaglycan glycosaminoglycan receptor. The glycoprotein receptors, 
TGFR-B I and II, are thought to mediate the effects of TGF-B 
whereas the betaglycan may function in pericellular TGF-B 
presentation13315. 
TGF-B is remarkedy pluripotent and its actions on cells are 
greatly dependent on cell type and differentiation state, TGF-B 
concentration, and the presence of other growth factors. There has 
been much work on how TGF-B affects the physiology of 
hepatocytes185, myocytes and myocardial infarction159*189a/b, 
steroid synthesis89, bone cells3*33, alveolar cells134, angiogenesis41, 
and development163. Findings from this work have great 
implications for both TGF-B research as well as clinical applications 
of TGF-B, findings which can not be summarized in this forum. 
What follows is, therefore, a description of TGF-B effects in systems 
which are especially pertinent to this thesis. 
TGF-B and the Immune System . Suppression of B- and T-cells; 
Inhibition of IgG/IgM production; Antagonism of IL-1 and other growth factors; 
Chemotactin and stimulant for macrophages. 
TGF-B decreases B- and T-cell growth and clonal expansion, 
decreases the generation of lymphokine-activated killer cells (LAKs), 
and decreases cytotoxic T-cell (CTL) growth58*!40. Recently, 
TGF-B has been found to inhibit thymocyte growth, especially 

thymocyte growth induced and supported by Interleukin-7. In this 
regard, TGF-B is immunosuppressive to the femto-molar range, 
making TGF-G 10,000 to 100,000 times as suppressive as 
cyclosporin- A9*114. TGF-B is, however, remarkably pleiotropic. 
While some reports describe TGF-B as a potent inhibitor of acute 
arthritic events19, others describe TGF-B as a potent inducer of 
synovial inflammation4’197^ 
TGF-B works to decrease antibody production of the IgG and 
IgM classes yet increases production of the IgA classes44’106- The 
hypothesis that TGF-B might function to increase the populations of 
IgA-bearing cells along respiratory and gastrointestinal epithelium is 
now being investigated197*1. TGF-B anatagonizes many of the affects 
of Interleukin 1 (IL-1), IL-2, and IL-3, Tumor Necrosis Factor- 
alpha (TNF-a), and Interferon alpha (IFN-a) on cytotoxic T-cell 
function and the development of Lymphocyte-Activated Killer Cells 
(LAKs)58. TGF-B downregulates IL-l-induced IL-6 production by 
human monocytes144. 
Whereas TGF-B is generally inhibitory for lymphocyte function, 
it tends to be stimulatory for macrophage and monocyte function. 
TGF-B is a chemoattractant for monocytes and macrophages, and 
increases macrophage membrane receptors for TNF-a, PDGF-AA, 
Fibroblast Growth Factor (FGF), IL-1, TGF-a, and TGF-B 
itself13°, 197a, 197b. TGF-B is also extremely potent in suppressing 
the superoxide (O') respiratory burst of macrophages and 
polymorphonuclear lymphocytes (PMNs), leaving the general 
impression that TGF-B suppresses the destructive effects of 

macrophages and acute cell activities while facilitating macrophage- 
derived factor function and the processes of tissue repair191. 
TGF-B and the Cell Matrix. Upregulation and support of matrix 
proteins via three mechanisms. 
Perhaps few other fields in TGF-B research have proven as 
intriguing as that of cell matrix biology and how the molecule 
regulates matrix formation and the activity of mesenchymal cells. 
TGF-B, the "gadabout growth factor"9, was eventually assigned a role 
that subserved many of its ostensibly disparate activities: the 
upregulation of matrix proteins133c. Three matrixogenic mechanisms 
have been thus far studied: 
(1) TGF-B increases matrix molecule production: TGF-B 
induces the production of certain matrix proteins like collagen types I, 
III, IV and V, fibronectin, thrombospondin, osteopontin, osteonectin, 
SPARC, and chondroitin and dermatan sulfates2’41’131’1332’148’196. 
TGF-B directly stimulates the promotors for a2(I) collagen as well as 
fibronectin, an influence mediated by an NF-1 binding site49. 
Furthermore, TGF-B directly increases fibronectin gene transcription. 
Most recently, Heine et al. have shown that TGF-B co-localizes with 
collagen I & III, fibronectin and glycosaminoglycans during lung 
branching morphogenesis80. Such observations suggest that TGF-B 
may be important in the regulation of matrix formation in development 
as well as in mature stages of life. 
(2) TGF-B increases receptors for matrix proteins: TGF-B 
induces the expression of the matrix protein receptors classed as 




(3) TGF-B inhibits matrix proteases: TGF-B can both 
inhibit the expression of enzymes which can degrade the matrix 
proteins, as well as induce the production of enzymes which inhibit the 
matrix-degrading enzymes57’164. Inhibition of the matrix protease 
transin, a member of the metalloproteinase family, has recently been 
found to involve a specific sequence in the transin gene promotor, the 
TGF-6 inhibitory element (TIE)10**,134,135. After TGF-B stimulation 
of the cell, the TIE sequence is bound by a trans-activating factor 
containing the c-fos protein, fos, thus implicating the c-fos oncogene as 
a mediator of TGF-B function in both cis- and trans-inhibition of 
transin gene expression and thus of matrix regulation 108. 
TGF-B and Bone. TGF-B is stored in bone; TGF-B is activated by 
osteoclasts; TGF-B may promote bone formation via several mechanisms; TGF-B may 
upregulate osteoblast cytoskeletal proteins. 
TGF-B is stored primarily in two locations in the body: in the 
alpha granules of platelets and in the matrix of bone33’55. There are 
approximately 1500 TGF-B molecules per platelet making platelets the 
richest source of the hormone. TGF-B in bone, however, is dispersed 
equally throughout the body skeleton making bone the largest source of 
TGF-B in the body (0.3 mg/kg)179. While platelet-derived TGF-B has 
been postulated to have roles in tissue repair, bone-derived TGF-B is 
thought to have roles in the regulation of bone remodeling, the 
continuous life-long process of resorbing and replacing bone with new 
mineralized tissue. Embryologically, TGF-B is actively expressed in 
the axial skeleton and, in older embryos, in the cytoplasm of osteoblasts 
involved in ossification processes30. 
Osteoblasts and certain osteosarcoma cells, have very high 
messenger RNA levels for TGF-B, and secrete high concentrations of 

the hormone28’35. Recalling that TGF-B is generally inhibitory for the 
growth of normal cells, it is surprising to observe that TGF-B is 
mitogenic for osteoblasts and inhibitory for osteoclasts, suggesting a 
pro-bone forming effect of the hormone33’24’47’157. These effects 
appear independent of prostaglandin production130. Mackie et al. have 
described a TGF-B-induced increase in bone formation while Chenu et 
al. have suggested that TGF-B acts as a chemotactic agent for osteoblast 
migration into a remodeling locus42’130. Although TGF-B upregulates 
extracellular matrix formation 158, Lomri et al. have shown that TGF-B 
can increase intracellular cytoskeletal proteins as well127. TGF-B 
upregulates collagens I & III production3 but inhibits production of 
collagen type II88. Particularly relevent to in vivo physiology of the 
hormone is the observation that osteoclasts activate TGF-B from its 
latent form when the hormone is released from the bone matrix. The 
activated TGF-B may then, in high local concentrations, upregulate the 
restoration of bone removed by the osteoclasts which activated the 
hormone. 
The Bone Morphogenetic Proteins (BMPs) are important 
hormones in osteogenesis and development and belong to the TGF-B 
superfamily. BMP-2B is a known inducer of endochondral bone and 
limb bud cartilage formation. TGF-B inhibits some of the effects of 
BMP-2B in chondrogenesis and may modulate the effects of the BMP 
family in v/vo41b. 
There is little data in the literature on the regulation of osteoblast 
cytokine secretion by TGF-B. Such a relationship between TGF-B and 
cytokine secretion could have profound effects on not only bone 
remodeling itself, but on the development of the neighboring colonies 

of bone marrow cells which could be stimulated by bone cell-derived 
cytokines. As this thesis presents the first data supporting a role for 
TGF-B activation of osteoblast-cytokine secretion, it would be 
advantageous to discuss briefly the major properties known about the 
bone cell-derived cytokines studied in this work, as follows concerning 
Interleukin-6 (IL-6), Interleukin-1 (IL-1), GM-CSF and M-CSF. 
B. INTERLEUKIN-1 Coley's toxins and LPS; Discovery of IL- 
1; IL-1A and IL-1B are processed differently; IL-1B is studied in this thesis._ 
In the late 19th century, William B. Coley, a New York City 
surgeon, observed that several patients of his with terminal cancer 
of comparable stage and who contracted low-grade Gram negative 
bacterial infection had less morbidity and metastatic disease than 
similar patients free of infection. Reviewing experiments by 
Germany's Pfeiffer on 'Gram negative' cell walls, Coley 
conjectured that there was some component of the causative 
bacteria which enabled the patient's body to fight neoplastic disease. 
Eventually, Coley isolated fractions of Gram negative bacterial 
cell walls, eventually called 'Coley's toxins', which he used with 
considerable success to treat several patients with bone and soft 
tissue sarcomas46,202# gy World War I, however, use of Coley's 
toxins fell into disfavor partly because the use of such toxins was 
accompanied by undesirable side effects including extreme nausea, 
confusion and a profound fever. It would not be known for fourty 
years that the effects of Coley's endotoxins were due to a molecule 
known as lipopolysaccharide (LPS). It would be sixty years 

before it was known that Coley's toxins, or the LPS moiety of 
endotoxin, had been inducing the body's production of a hormone 
called Interleukin-1, the isolation of which has revolutionized 
immunological science. In 1942, Menkin et al. characterized the 
physiologic responses to the administration of endotoxins136. 
After an intravenous dose of 25 mg/kg of endotoxin, animals 
Figure II.vi. Dr. William B. Coley, Surgeon (1926), 1862-1936. In the late 19th 
and early 20th centuries, Coley became the first investigator to use biologic 
molecules in attempts to potentiate the immune reponse to cancer. His 
preperations of endotoxins were later determined to contain lipopolysaccharide 
(LPS), one of the most potent inducers known of IL-1 synthesis and release, the 
probable mediator of endotoxin immunopotentiation. Photograph courtesy of the 
New York Academy of Medicine Library. 

expressed a profound, acute fever often as high as 39.5 degrees 
Celsius. Menkin termed the causative molecule pyrexin and 
believed that fever was caused by endotoxin-induced pyrexin and 
not by endotoxin itselfI36. In 1949, Beeson eventually isolated a 
protein candidate in granulocytes for pyrexin, a protein he termed 
'granulocyte pyrogen' or GP12. There was much debate on 
whether pyrexin and GP were actually pyrogenic or whether 
endotoxin itself caused fever. In 1970, however, Bodel was the 
first to show that a 14-15,000 Dalton protein, isolated from 
endotoxin-stimulated granulocytes, could cause fever, a molecule 
termed the Leukocyte Endogenous Mediator, or LEMl8. By 
1971, several laboratories, including Gery et al.67, Oppenheim et 
al.151, and Calderon et al.27 began describing a soluble factor 
produced by stimulated macrophages which increased thymocyte 
DNA synthesis. The activating entity was termed Lymphocyte 
Activating Factor, or LAF, produced by macrophages exposed to 
bacterial endotoxins (LPS) or lectins (PHA)l7. Using similarly- 
activated macrophages, laboratories began describing a wide 
variety of activities induced by a soluble factor(s). Besides LEM 
and LAF above, other workers described an inducer of acute phase 
protein synthesis called Hepatocyte Activating Factor, or HAF, an 
inducer of muscle wasting termed catabolin, an inducer of bone 
resorption termed Osteoclast Activating Factor, a stimulator of 
primitive hemopoetic cells called Hemopoeitin-1, and an inducer of 
serum proteins known as Amyloid-A Stimulating 
Factor50,51,55,139,156# However, with the initial purification of 
LAF by Blyden and Handschumaker in 197418, it was found that 

all of the above activites could be attributed to one, single 
molecule51. With the observation that the molecule was 
macrophage-derived and could stimulate other white cells, 
including T-cells, the molecule was eventually known as 
Interleukin-1 (IL-1). Additional characterizations of IL-1 
determined that at least two related proteins exist with IL-1 
activity, differing in isoelectric point (pi) and various tertiary 
configurations- IL-1 a and IL-1 13 with pis of 7.0 and 5.0, 
respectively1 lla.207. Despite differences in homology and trans¬ 
species conservation, IL-1 a and IL-1- B are ligands for the same 
receptor and have, in general, identical modes of action. The IL-1 
a gene is located on chromosome 2 in the mouse and is remarkable 
for the absence of any upstream enhancer sequences like TATA, or 
CAAT63. The 10206 base pair gene is transcribed into a 2.3 
kilobase (kB) message, and translated into a 268-271 amino acid 
precursor of 38 kDaHll)*141, IL-1 B is also located on murine 
chromosome 2, but has several TATA and CAAT enhancer 
sequences just upstream of the Start point. The 7008 base pair gene 
is transcribed into a shorter 1.4-1.8 kB mRNA, and translated 
into a similar 33-38 kDa precursor of 266-269 amino acids^3. 
Both proteins must be cleaved in an as-of-yet undetermined process 
to yield the mature 17-18 kDa polypetides16’50. Neither protein 
has an N-terminal hydrophobic secretory signal suggesting that IL- 
ls are released by a unique mechanism, possibly via cleavage by 
species-specific membrane proteins. Kobayashi et al. have 
presented the model whereby precursor IL-1 a is phosphorylated 
and then associated with a calcium-dependent acidic phospholipid 

on the membrane outer surface which releases mature IL-1 alllb. 
In contrast, IL-1 B, which is released earlier and faster than IL-1 
a, is thought to be bound without phosphorylation to a trans¬ 
membrane processing protein, which releases mature IL-l-B. 
Recently, Bakouche et al. have presented data suggesting that 
mature IL-1 is released via lysosomal vesicles8a>8b. 
In 1982, Auron et al. eventually cloned a cDNA from activated 
human macrophages, and both species of human IL-1 cDNAs were 
cloned, sequenced and expressed by 19857. 
Cell Sources of IL-1 In Vivo. Produced mostly by activated 
macrophages, but also by T-cell classes, keratinocytes and osteoclasts. 
By far, the largest source of Interleukin-1 is derived 
from the phagocytic leukocytes: peritoneal and tissue macrophages 
and blood monocytes, from which IL-1 was first purified in low 
picomolar concentrations18. Kupper et al. have shown that non- 
stimulated keratinocytes are active secretors of IL-1 a, a finding 
that continues to have great implications in 
immunodermatology116^1^. Muegge described IL-1 production 
by killer T-cells in the late 1980’s and then found IL-1 in y/S T- 
cells as well. Although mice make more IL-1 a than IL-1 B, IL-1 
B is believed to be the more active isoform in macrophage biology 
and is the IL-1 species studied in this thesis. 
Activities of IL-1 Perhaps few other molecules in 
biological research have been implicated in as many diverse 
systems of physiology as Interleukin-1. Summarized here will be 
only those activities of the hormone which are most relevent to the 
studies in this thesis, although the interested reader may be referred 
to several excellent reviews 50,55. 

i. Stimulation of T- and B-cells. Induces IL-2 
production; IL-1 may activate B-cells. 
Larrson et al. first presented data in 1980 
demonstrating that T-cell production of T-cell derived growth 
factor (TCGF), now known as Interleukin-2 (IL-2), was supported 
by a 20 kDa molecule derived from macrophages, later identified 
as Interleukin-1123. The observations were some of the first to 
characterize the crucial T-cell/macrophage axis, perhaps the most 
important arm of the early activation of the immune system. IL-1 
secretion and consequent IL-2 production can greatly increase T- 
cell clonal expansion and proliferation. Furthermore, IL-1 can 
synergize with IL-2 to enhance IL-2 responsiveness 132. 
B-cells can be stimulated at precursor stages and after 
exposure to antigen by T-cell derived cytokines like B-cell Growth 
Factor (BCGF) and Interferon-gamma (IFN-y) and possibly IL- 
2125. Several laboratories have shown that B-cells in quiescence 
can be brought to Gi, driven into mitosis1**!, and eventual 
immunoglobulin secretion by Interleukin-1 and the T-cell-derived 
cytokines !25. 
ii. Stimulation of acute phase cells, acute phase proteins 
and features of inflammation. 
IL-1 is a potent chemotactin and degranulator 
for neutrophils, eosinophils and other macrophages, implicating the 
hormone as an amplifier and director of early stages of 
inflammatory events. IL-1, formerly studied as Hepatocyte 
Stimulatory Factor (HSF), can induce a large spectrum of acute 
phase proteins from liver cells in vitro (see below) 156,161 IL-1 
also induces arachidonic acid metabolism, with the consequent 

production of leukotrienes and prostaglandins50. Glucocorticoid 
therapy for inflammation may down regulate prostaglandin 
synthesis in at least two ways- inhibition of cylooxygenases, and by 
inhibiting transcription of the IL-1 gene via a Glucocorticoid 
Binding Element (GBE) 50. 
iii. Induction of M-CSF. GM-CSF. and IL-6 synthesis. 
Kaushanksy et al.104 and Zucali et al.214 
have presented data on dermal fibroblasts showing that IL-1 can 
induce the production of Granulocyte-Monocyte CSF (GM-CSF) 
and Granulocyte-CSF (G-CSF). IL-1 did not, however, induce the 
production of Macrophage-CSF (M-CSF) in the Kaushansky 
group's studies. Stanley et al.184, and Bartelmez et al.10, studied 
Hemopoetin-1 (H-l), a growth factor isolated in 1985 from human 
bladder carcinoma cells and later determined to be IL-1 itself. 
Data indicated that although H-l alone had no effect on colony 
stimulation in vitro, H-l synergized with other colony stimulating 
factors, like M-CSF (CSF-1) and Interleukin-3 (IL-3), to induce 
hematopoesis at earlier stages than either M-CSF or IL-3 alone. 
Several workers have also described the induction of 
Interleukin-6 (IL-6) production in fibroblasts by IL-1177. Released 
IL-6, as reviewed above, may stimulate both hematopoesis as well 
as the synthesis of C-reactive and acute phase proteins65,161 IL-6 
may mediate some IL-1 effects. Such evidence implicates IL-1 not 
only in early stages (0-12 hours) of immunoreactivity against 
foreign invasion, but the later stages by inducing potentially 
immunoreactive cell precursors towards maturity. 

iv. Interactions with complement. C5a induces macrophage IL- 
1 synthesis; IL-1 can activate C3 and Factor B. 
Macrophages do not constitutively secrete IL- 
1, but will produce large amounts when exposed to complement 
products such as C5al42b. In turn, IL-1 stimulates hepatocyte 
production of Complement factors 3 and B156,161. As more 
species of animal systems were described for IL-1 activities, it 
became clear that the molecule had an extraordinary degree of 
conserved homology, even over presumably large evolutionary 
divisions. Human IL-1, for example, shares 95 % homology with 
primate IL-1 (chimpanzee) and 90% homology with the horseshoe 
crab (Figure ILxii). Starfish Factor B, derived from coelemic 
phagocytes, is now known as Interleukin-1H. It was the presence 
of active IL-1 in echinoderms that suggested IL-1 was extremely 
old, since horseshoe crabs are believed to have changed little since 
the late Jurassic period (160-140 million years ago). There is 
evidence that IL-1 may induce the alternate pathway of the 
complement cascade and is induced by complement products like 
C5a (see figure Il.xii)142. Such observations suggest that IL-1 may 
have operated in simple immune systems, like those of the 
echinoderms- devoid of antibody production but dependent upon 
coelemic phagocytes and phagocyte-derived IL-1 to induce 
inflammatory changes. 
v. Pvrogenesis and prostaglandin E? production . IL-1 8 
induces fever by increasing hypothalamic PGE2 mediated perhaps by CRF. 
IL-1 was originally studied as the LEM, or 
Leukocyte Endogenous Mediator, or simply, the Endogenous 
Pyrogen (EP), as the inducer of acute rises of body core 
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temperature to levels of fever. Although there exist other 
cytokine pyrogens, like IL-6, Tumor Necrosis Factor and 
Interferon a, IL-1 is at least 50 times as potent, acting as a pyrogen 
in doses of 2 ng/kg55. IL-1, and the other pyrogenic cytokines, 
most likely induce fever by inducing the synthesis of prostaglandin 
Figure ILvii. Left, the horseshoe crab, Limulus polyphemus, one of the oldest 
animal species on earth. The crab's coelom is patrolled by host phagocytes which 
are active producers of an Interleukin-1 species that is 95% homologous to human 
IL-1, and which may be involved in a complement-dependent type of primitive 
immune system. Right. IL-1 activation of the alternate complement cascade, 
effective in generating Membrane Attack Complexes (MACs) in the absence of 
antibody. IL-1 induces C3 and B synthesis in hepatocytes thus fueling the 
cascade. Production of C3a and C5a may contribute to IL-1 mediated 
inflammation and hypersentitivity reactions, (ap) = anaphylatoxins. 
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E2 (PGE2). Endotoxin, or LPS exposure, leads to increased 
levels of PGE2 in the brain, spinal fluid and in the 
hypothalamus24’174. As shown below in figure Il.xiii., released 
PGE2 in the brain may trigger heat controlling centers in the pre¬ 
optic nucleus of the anterior hypothalamus which, in turn, 





Figure II. viii. IL-1 pyrogenesis and the IL-1 pituitary-adrenal axis. Endotoxin- 
induced release of IL-1 leads to increased hypothalamic PGE2, resetting 
hypothalamic autonomic outflow to raise body temperature. The PGE2 also 
functions to release CRF from the hypothalamus which induces the release of 
ACTH from the anterior pituitary. Cortisol, produced in the adrenal cortex after 
ACTH stimulation, functions to directly suppress macrophage production of IL- 
1, thus acting as the negative feedback arm of the axis. 

body temperature to rise. IL-1 may have direct effects on the 
hypothalamus as well. Although it is believe IL-1 resets 
hypothalamic temperature regulation via prostaglandin synthesis, 
Busbridge et al. have presented evidence suggesting at least some of 
IL-l's pyrogenicity may be mediated by Corticotropin Releasing 
Factor (CRF)24. It was first noted in 1986 by Besedovsky et al.14 
and Uehara et al.i93 that IL-1 participated in a hypothalamic 
pituitary-adrenal axis by inducing hypothalamic release of CRF and 
consequent adrenocorticotropic hormone (ACTH) from the 
anterior pituitary. Glucocorticoids released from stimulated 
adrenal glands then inhibited in a feedback mechanism ACTH 
release, CRF release and IL-1 release from leukocytes. Clinicians 
had used endotoxin itself as a common clinical test for anterior 
pituitary-adrenal axis function24. However, Busbridge et al. 
found that IL-1 13-induced fever could be blocked by both anti-CRF 
antibody and CRF receptor antagonists. IL-1 a-induced fever 
could not be similarly blocked. IL-1 6 mRNA is expressed in the 
hypothalamus but IL-1 a mRNA is not24. Further studies, 
especially in vivo studies of brain tissue, will be needed to clarify 
these observations. IL-1-induced fever is probably an important 
mechanism of heightening the immune system in the bodys general 
response towards foreign invasion, although the exact function of 
hyperthermia in pathologic states is not yot clear. 
vi. Interleukin-1 and Bone. Osteoblasts express receptors for 
IL-1 while osteoclasts do not. IL-1-induced effects on osteoclasts may be 
regulated via osteoblast-derived factors. 
As early as the 1880s, clinical descriptions of 
multiple myeloma have included reports of abnormal bone 

resorption and associated sequellae: hypercalcemia, profound 
osteoporosis, bone fractures and bone pain. Bone pathology is a 
hallmark of multiple myeloma and is one of the most debilitating 
aspects of the disease. Myeloma cells can elicit hormones as 
Osteoclast Activating Factor (OAFs) which activate osteoclasts to 
resorb bone unchecked by normal controls94. OAFs include 
Tumor Necrosis Factor 6 and IL-1B. Some workers suggest IL-1 
is less important in vivo as an OAF83 but IL-1 in vitro is 10 times 
more potent than TNF for decreasing proteoglycan synthesis in 
cartilage171. 
Osteoblasts express receptors for IL-1 while osteoclasts do 
not167c. IL-1, however, has been found to increase osteoclast 
development, osteoclast precursor number69,!87? and osteoclast 
collagenase production78. IL-1 stimulates osteoblast production of 
Macrophage-Colony Stimulating Factor which may then act, in a 
paracrine fashion, to induce the development of 
osteoclasts7713’128b,206# Paracrine activity by osteoblasts may be 
important in mediating the other effects of IL-1 on osteoclast 
development outlined above. 
IL-1 may induce bone resorption by increasing local 
prostaglandin E (PGE) production110’172 but other workers 
suggest a direct resorptive effect147. PGE as a single agent is a 
potent inducer of matrix resorption in vivo110. IL-1 induced bone 
resorption is decreased by TGF-B157. Such findings suggest that 
IL-1 may be an important mediator in the regulation of bone 
remodeling. 

The IL-1 receptor and IL-1 signal transduction 
The determination and analysis of the IL-1 receptor was 
greatly facilitated by the cloning and expression of purified IL-1 
from isolated cDNAs in 198650’56’207. Early experiments reported 
receptor protein candidates with several molecular weights, but after 
the isolation of receptor cDNAs, it was determined that the IL-1 
receptor was a single glycoprotein of 80 kDa15. The complete 
amino acid sequence has been determined including a membrane 
spanning domain of 21 amino acids2’2!. Putative protein kinase C 
acceptor (Gly-x-Gly-Ser-x-Ser)90,92 and cAMP binding sites have 
also been identified29’77. Despite this initial data, however, it is still 
unclear how the IL-1 receptor transduces ligand binding into 
intracellular signalling2’^, 138,150# 
Many hormone receptors transduce extracellular stimulation by 
utilizing second messenger systems to activate specific intracellular 
kinases: cyclic nucleotide hydrolysis for activation of cGMP/cAMP- 
dependent kinases or phospholipid hydrolysis for calcium/diacyl 
glycerol-dependent kinases14’92’153. There is much debate 
concerning which second messenger system predominates in the IL- 
1-stimulated cell. Many transcription factors and co-factors are 
activated by IL-1 so the second messenger systems which mediate the 
IL-1 response may be complex. 
Mizel et al. provide evidence of protein kinase A activation by 
cAMP hydrolysis in IL-1 stimulated T-cells150. In contrast, other 
workers report that IL-1 does not raise T-cell cAMP levels and has 
no effect on intracellular levels of diacylglycerol, calcium, or 
phosphoglycerides^BSJSO. O'Neill et al. have found that a 

stimulatory G protein activates a novel serine kinase in IL-1-exposed 
T-cells. Rosoff et al.168 have presented data concerning Jurkatt T- 
cells that suggest IL-1 may transduce its signal not via classical PI 
hydrolysis, but rather through a novel hydrolysis of membrane- 
bound phosphotidylcholines (PCs). The Rosoff group showed that 
Figure Il.ix. Theories of signal transduction by the IL-1 receptor in T-cells. As 
suggested by Rosoff et al.168, T-cell co-stimulation by LL-1 and anitgen may be 
achieved through the production of differing species of diacylglycerols (DAGs) 
and the synergistic activation of trasncription factors (TFs). As illustrated above, 
antigen stimulation of the T-cell receptor induces classic PI turnover with the 
production of free intracellular calcium (not shown) and diacylglycerol species 2 
(DAG-2). IL-1 induces hydrolysis of rapidly-shuttled phosphatidylcholine (PC) 
for the production of calcium (not shown) and diacylglycerol species 1 (DAG-1). 

DAG-1 and -2 activate species-specific protein kinases C (PKC-1 and -2), 
respectively. PKC-1 and -2 synergize to activate transcription factors (TFs) or 
enhancers. IL-1 may have hydrolyzing capabilities and may hydrolyze PC 
directly (a). Altemativately, IL-1 may hydrolyze PC via a membrane-bound 
hydrolase (b) or through a classic IL-1R and an associated phospholipase (c). 
IP3=inositol triphosphate, MHC=multiple histocompatability, APC=antigen 
presenting cell, PLC=phospholipas C, PLX=putative phospholipase, PIP2= 
phosphotidylinositol diphosphate, PCv=vacuolar PC, PCm=membrane-bound 
PC, TFi/TFa=inactive/active TF. 
PC hydrolysis after IL-1 stimulation produces diacylglycerol 
(DAGs) species with different fatty acid side chains than DAGs 
produced by PI hydrolysis after antigen stimulation. 
Furthermore, IL-1 induces PC hydrolysis on outer cell membranes 
and on many internal membranes as well, liberating DAG 
molecules throughout the Jurkatt cell cytoplasm. Jurkatt T-cells, 
however, as assayed by Rosoff et al.168, have no IL-1 receptors, 
or at least less than 200 receptors per cell. Rosoff suggested that 
IL-1 may have dual effects on a cell. First, IL-1 may be a ligand 
for a low number, high-affinity IL-1 receptor. Secondly, IL-1 
may have intrinsic PC-hydrolyzing ability and may directly initiate 
outer membrane-bound PC hydrolysis without a receptor 
intermediate. 
Signal transduction by IL-1 is still, therefore, unclear, but an 
important model arises with particular relevance to this thesis as 
presented in figure II. ix. : IL-1 induces PC hydrolysis, via 
unknown pathways, to increase DAG production throughout the 
cell. Concomitantly, a secondary signal, antigen, lectin or OKT3 
antibody against the T-cell receptor (TCR), initiates TCR signal 
transduction via classical PI hydrolysis with the production of other 
DAG species and free intracellular calcium. The two differing 
species of DAGs may act on different protein kinases C or A and 

synergize for transcription factor or co-factor cativity. The 
utilization of two seperate signalling pathways which converge 
upon and synergistically activate common trans- or cis- gene 
activators may be an important mechanism of cellular activation 
with importance to the discussion of data presented in this work. 
C. INTERLEUKIN 6 Discovery of the roles of IL-6 in 
B-cell maturation; IL-6 production; In vivo sources of the hormone._ 
The immune system relies heavily upon B-cells to produce 
antibody against specific antigens foreign to the host. The only 
antibody producing B-cells, however, are those B-cells which are 
fully differentiated and appropriately stimulated with antigen. 
These two conditions may be achieved by the presence of T-cells and 
antigen-presenting macrophages. By 1982, it was clear that certain 
soluble growth factors could substitute for the apparent function of 
T-cells and macrophages in the process of B-cell stimulation!76’21 L 
In 1986, three of the putative growth factors were isolated and 
cloned 109. As illustrated in figure II. vi below, the first factor was 
Interleukin-4 (IL-4), originally called B-Cell Growth Factor-1 
(BCGF-1) or B-Cell Stimulatory Factor 1 (BSF-1) because the 
molecule functioned to activate early B-cell progenitors exposed to 
antigen. The second factor was Interleukin-5 (IL-5), then known as 
BCGF-2, which functioned to induce growth in activated B-cells. 
The third factor functioned to induce the differentiation of growing, 
activated B-cells into antibody-producing B-cells. This third factor, 
originally called B-cell Differentiation Factor (BCDF) or B-cell 

Stimulatory Factor 2 (BSF-2), is now known as Interleukin-6 (IL-6). 
Like Tumor Necrosis Factor (TNF) and Interleukin-1 (IL-1), IL-6 
Figure II.x. The B-cell growth factors. Pre-B cells are activated (act-B) by IL-4 
and express receptors for IL-5, which in turn, stimulates activated cells to assume a 
'primed' state (B'). Only then can IL-6 induce such cells to synthesize and secrete 
antibody. IL-7 may funtion to upregulate pre-B cell growth and differentiation. 
was also studied as the major inducer of acute phase protein 
synthesis, and in this regard IL-6 vvas also known as Hepatocyte 
Stimulatory Factor (HSF)31’165 Like many growth factors, IL-6 is 
a small protein of 184 amino acids. Mouse and human IL-6 DNA is 
60% homolgous for the gene coding region, but 90% homologous 
over 300 base pairs at the extreme 5' end of the gene suggesting an 
important regulatory site. Additionally, the 5'-flanking sequences 
of each exon in the gene is similar to previously identified 
transcription enhancer elements like the serum reponse elements 
(SRE) of c-fos, the Early Growth Response genes, or the 
glucocorticoid receptor binding element (GRE)109,188 Although 
mouse and human IL-6 protein are only 42% homologous, the two 
species are 100% homologous in the position of the four cysteine 
residues in the molecule. Such cysteine homology is also shared by 

a hematopoietic growth factor called G-CSF suggesting that cysteine 
residues may be important to IL-6 and G-CSF activity. 
IL-6 is produced by T- and B-cells, monocytes and macrophages, 
fibroblasts, keratinocytes, endothelial cells, some tumor cells, and 
osteoblasts60’76’84. IL-1 is a potent inducer of IL-6 production in 
these cells, an effect inhibited by TGF-BI44. 
Roles of IL-6 in the immune system. T-cell activation; Mediation 
of IL-18; Lennert's disease. 
Unlike resting B-cells, resting T-cells express surface 
receptors for IL-6. Once stimulated with IL-6, T-cells express 
receptors for Interleukin-2 (IL-2), the T-cell growth factor109. IL- 
6 also stimulates the production of serine esterases in T-cells, an 
enzyme crucial to T-cell cytotoxicity109. IL-6 was identified as the 
soluble factor in addition to IL-2 that was necessary for the induction 
and growth of cytotoxic T-cells (CTLs)39. In vivo, T-cell 
stimulation by IL-6 may most likely be achieved by constitutive IL-6 
production by macrophages. IL-6 may mediate the effects of IL-l-B, 
an effect ablated by TGF-B51’144. The importance of this cellular 
relationship is illustrated clinically in Lennert's T-cell lymphoma, a 
non-Hodkin's lymphoma. In Lennert's disease, massive infiltration 
of lymphoid tissue by macrophage-derived histiocytes is 
accompanied by the growth of T-cell lines which are dependent upon 
the presence of the infiltrating macrophages109. IL-6 in vitro may 
substitute for macrophages in supporting the growth of Lennertine 
T-cells because antibody to IL-6 completely abrogates the growth 
effects of the macrophages upon the T-cells175. 

Roles of IL-6 in hematopoiesis. Blast cell activation with 
IL-3 for granulocyte-monocyte lines; Role in megakaryocytopoiesis; Activity in 
multiple myeloma; Uses of IL-6 in transplantation medicine. 
IL-6 has a potent ability to induce hematopoietic 
stem cells from the quiescence of Go into the active growth of Gi. 
A second growth factor, Interleukin-3, can stimulate such activated 
blast cells to grow and differentiate along various lineages into blast 
cell colonies. Although granulocyte-monocyte lines typically 
develop from stimulated blast cells, Koike et al. have shown that IL- 
6 also upregulates megakaryocytopoiesis112. Murray et al. 
demonstrated that IL-6 mRNA is clearly expressed in 4-day old 
murine blastocysts suggesting that IL-6 may be important in 
embryonic stem cell development and the first stages of 
hematopoiesis 143. 
The synergistic interaction of IL-6 with IL-3 for the 
establishment and growth of blast cell colonies in vivo may also be 
important in clinical science; IL-6 and IL-3 have already been used 
to super-induce the formation of bone marrow cultures in 
preparation for transplantation. In fact, Okana et al. has observed 
that transplanted marrow cells which were pre-cultured with IL-6 
before exposure to IL-3 had a survival rate of 90% while non- 
cultured marrows had only a 20% survival rate149b. 
IL-6 is a strong stimulator of growth in myeloma cells and 
plasmacytoma cells, and anti-IL-6 abrogates such growth. Myeloma 
cells also produce IL-6 and are therefore likely to maintain cell 
growth via this autocrine mechanism109. 

Roles of IL-6 and the endocrine system. The pituitary- 
adrenal axis; Suppressionof IL-6 with dexamethasone. 
As illustrated in figure II. vii below, IL-6 induces the 
release of corticotropin releasing hormone (CRH), which functions 
to induce the release of adrenocorticotropic hormone (ACTH)146. 
ACTH stimulates adrenal cortex cells to produce glucocorticoids, 
which, in turn, function to inhibit IL-6 production. Both IL-6 and 
glucocorticoids function to induce acute phase proteins^ 1,32. 
Glucocorticoid suppression of IL-6 production suggests an important 
feedback mechanism in the regulation of the molecular response to 
stress. 
Figure II.xi. The pituitary-adrenal IL-6 axis. IL-6 induces the release of 
corticotropin releasing hormone (CRH) from the hypothalamus. CRH, in turn, 
induces adrenocorticotropic hormone (ACTH) release from the anterior pituitary. 
Finally, adrenal cortisol, produced secondary to ACTH stimulation, functions to 
both down-regulate hypothalamic IL-6 receptors as well as decrease systemic IL-6 
production itself. 

IL-6 in bone. Produced by osteoblasts in response to various 
stimuli; Implicated in osteoclast formation; Role in osteobiology unclear. 
Normal primary osteoblasts do not constitutively express IL-6 
mRNA but will transcribe IL-6 genes and produce and secrete IL-6 
in response to numerous stimuli including exposure to 
lipopolysaccharide (LPS)85,87? Interleukin-1 (IL-1)17L172, and 
parathyroid hormone (PTH)84. The role of IL-6 in normal or 
pathologic bone and calcium metabolism, however, is not clear. 
There have been reports that IL-6 can stimulate proliferation 
and differentiation of osteoclast precursors117, potentiate IL-1- 
mediated bone resorption117 and inhibit osteoclast activity64. 
Glucocorticoids may inhibit IL-1-induced bone resorption by 
decreasing IL-6 mRNA production and hormone secretion94. 
Although these studies implicate IL-6 in a feedback mechanism 
between osteoblasts and osteoclasts to regulate local ratios of bone 
formation to bone resorption, data has not been widely confirmed. 
IL-6 may be produced by osteoblasts in fracture sites. This IL-6 may 
chemoattract and activate local acute and chronic phase cells of 
inflammation and repair. Evidence is presented is this thesis that 
suggests LPS-, IL-1- or PTH-induced IL-6 production by 
osteoblasts can be greatly accelerated and increased by cell priming 
with Transforming Growth Factor-Beta. 

THE COLONY STIMULATING FACTORS (CSFs) 
Every second of human life consumes 500,000 granulocytes, a 
number of cells which must consistently be replaced to avoid a 
systemic decrease in granulocyte number and the life-threatening 
condition of granulocytopenia. Granulocytes, and all other cell 
types normally present in the blood, arise from progenitors in the 
bone marrow, as the final cellular stage of long lineages in 
hematopoetic development. The reverse pyramid of blood cell 
formation is thought to be initiated by the growth of one single 
stem cell, a pluripotent progenitor of all cell types. During times 
of blood cell need such as infection or anemia, the marrow can 
produce up to ten times the baseline number of cells in as little as 
48 hours suggesting that the development of stem cells into fully 
differentiated cell types can be regulated. In the 1960's, the 
development of semi-solid media enabled researchers to establish 
cell culture systems for cells normally present only in bone 
marrow; cell progenitors which eventually differentiate into 
mature colonies of granulocytes, monocytes/macrophages, 
megakaryoctyes, etc. Using semi-solid media systems, it was 
found that cell types could not sustain cell division for more than 
48 hours in media alone. Rather, cell colonies could be initiated 
and sustained when certain fractions of marrow serum were 
included in culture. Specfic regulatory molecules were isolated 
from serum, and, since the molecules were identified by their 
ability to induce the growth of cell colonies, such molecules were 
referred to as Colony Stimulating Factors, or CSFs137b. Because 
the CSFs were present in extremely small amounts in vivo , it 

required many cycles of high-performance liquid chromatography 
to concentrate the molecules to analytical levels, in some cases, one- 
million times the concentration in vivo. Eventually, four distinct 
CSFs were isolated and cloned from murine and human bone 
marrow. As the properties of the CSFs began to be elucidated it 
was found that the molecules affected not only disparate branches 
of the hematopoetic family tree, but affected cells at certain stages 
of differentiation (figure Il.xii). Therefore, one CSF affected the 
early, common progenitor for both granulocytes and monocytes, 
and is therefore called Granulocyte-Macrophage CSF, or GM-CSF. 
A second induced the growth of only those cells which developed 
into macrophages (Macrophage-CSF, or M-CSF) and a third, 
Granulocyte-CSF (G-CSF), was an inducer of relatively well- 
differentiated pre-granulocyte colonies. The fourth, Interleukin-3, 
was by the far the earliest effector of cellular growth, inducing the 
proliferation of almost all cell types, including stem cells 
themselves. Since the CSFs are important in normal cellular 
growth, the hormones have also been implicated in disorders of 
excessive white blood cell growth (leukemia, thrombocythaemia), 
and of reduced white blood cell growth (granuloctyopenia, 
thrombocytopenia). Successful clinical trials in the treatment of 
neutropenia (acquired and intrinsic) have only heightened the 
interest in studying the CSFs as important hormones in disease and 
medical treatments. 
Despite the importance of the CSFs in blood cell formation, 
they possess other activities in vivo , and are made by non¬ 




Figure Il.xii. Hematopoetic growth factors and cell lineages. An unknown 
factor induces stem cell proliferation and early maturation. It is not known how 
early ultimate cell fates are determined. Blood Forming Units-Erythroid (BFU- 
E), Colony Forming Units-Megakaryocyte (CFU-Meg) and -Eosinophil (CFU- 
Eo) are formed early. CFUs-Granulocyte/Monocyte (CFU-GM) form an 
immense pool of precursors, from which are derived all neutrophils, 
macrophages, osteoclasts, and other tissue phagocytes. 
osteoblasts85. Osteoblasts make large amounts of GM-CSF and M- 
CSF in response to various stimuli like lipopolysaccharide (LPS), 
Interleukin-1, and parathyroid hormone60’86’87’204. 
D. GRANULOCYTE-MACROPHAGE CSF (GM-CSFh GM- 
CSF is a monomeric protein whose cDNA was eventually isolated 

and cloned in 1985 by Wong and coworkers209. Four cysteine 
residues are required for the two disulfide intramolecular bonding 
necessary for activity. Precursor proteins are processed only at 
the amino end to yield a 23-24,000 Dalton (Da) mature molecule, 
capped by an alanine-proline dimer at the amino terminus. The 
size of the GM-CSF species is determined by the number of the 
two asparagine sites in the protein which are glycosylated52. 
Double-site glycosylation will yield molecules which are 50% 
carbohydrate by weight52^. The sugar moieties have no apparent 
function in vitro and, in fact, decrease the growth promoting 
activities of the molecule. 
GM-CSF & Hematopoesis. Stimulation of multiple 
lineages at different points of maturity. 
GM-CSF affects granulocyte and monocyte 
formation by stimulating certain progenitor cells at various time 
points in hematopoesis, from very early to very late. As illustrated 
above in figure Il.xii, GM-CSF has been shown to stimulate some 
of the first daughters of stem cell division. The stimulated cells 
form colonies, or colony forming units (CFUs), from which are 
derived all non-lymphoid blood cells; granulocytes, erthyrocytes, 
monocytes, and megakaryocytes and thus are called CFU-GEMMs. 
GM-CSF stimulation of CFU-GEMMs induces the production of 
more differentiated colonies of cells, committed to four other 
lineages. One, an erythroid burst forming unit (BFU-E) is further 
stimulated by GM-CSF, IL-3 or erythropoetin to form erythroid 
CFUs and then reticulocytes. A second lineage, a megakaryocytic 
CFU (CFU-MEG) is first stimulated by IL-3 and GM-CSF and then 
by erythropoetin to form mature megakaryocytes. A third lineage, 

CFU-Eo, is stimulated by IL-3 to form basophils and by both IL-3 
and GM-CSF to form eosinophils. The fourth lineage develops 
into a CFU for granulocytes and monocytes, CFU-GM. 
Stimulation of CFU-GMs by IL-3 and GM-CSF induces the 
production of monocytes. GM-CSF stimulation of monocytes, in 
turn, induces maturation into tissue and blood macrophages. 
Stimulation of CFU-GMs by IL-3, GM-CSF, and Granulocyte-CSF 
(G-CSF) produces mature neutrophils. 
Sources of GM-CSF in vivo. Lack of evidence for 
constitutive release in marrow; Production og GM-CSF by activated T-cells, 
macrophages, and osteoblasts. 
The requirement that the marrow produce blood 
cells at different rates throughout an individual's life points to the 
regulation required for the production of GM-CSF and the other 
hematopoietic hormones. Furthermore, normal cells thus far 
examined constitutively express minute quantities of GM-CSF 
messenger RNA, suggesting that the hormone is produced only 
when needed. Isolatable quantities of hormone are obtained from 
cells, such as murine alveolar cells, only after stimulation, i.e. with 
endotoxins23. T-cells209, stromal cells21!, and osteoblasts86 will 
all produce quantities of GM-CSF after appropriate stimulation 
with endotoxin or tumor necrosis factor (TNF). Such 
observations support the hypothesis that the rapid induction of 
acute phase cell growth during times of infection is achieved after 
the release of GM-, G-, and M-CSFs from activated cell types. 
Although one may implicate GM-CSF in the maintainence of 
normal, steady-state hematopoesis, no definitive data yet exist to 
show that the hormone is constitutively produced in the bone 

marrow. Because of GM-CSF's low concentration in vivo, it may 
be difficult to detect constitutive secretion of the hormone by 
marrow stromal cells into microenvironments to induce CFU 
activity. 
GM-CSF and osteoblasts. Produced by stimulated 
osteoblasts; Hypersecretion in the transgenic TAX mouse; Growth factor in 
osteosarcoma. 
In 1988, Horowitz et al.86 showed that osteoblasts 
secreted large quantites of GM-CSF when appropriately stimulated 
with 1-10 nM parathyroid hormone or 1-10 pg/ml of 
lipopolysaccharide (LPS), the mitogenic component of Gram 
negative bacterial cell wall endotoxin. In situ hybridization data 
suggested that no messenger RNA for GM-CSF is consitutively 
expressed in osteoblasts but message levels are greatly increased 
after a 24 hour hour exposure to LPS86. GM-CSF is not 
mitogenic for osteoblasts but may positively affect the development 
of osteoclasts128b’l67c. GM-CSF does not affect levels of other 
bone-regulating hormones like PTH, calcitonin, or 1,25 (OH)2- 
vitamin D387. A new approach to the study of the hormone in 
bone has been established using a mouse strain transgenic for the 
transactivating (TAX) gene from the Human T-cell Leukemia 
Virus -1 (HTLV-l)l69. The transgenic animals were originally 
designed to study the effects of the TAX gene on immune function 
but were observed to have striking bone abnormalities, such as 
evidence of greatly increased rates of bone turnover and 10-fold 
increases in osteoclast number169. The TAX gene, by definition, 
activates other genes in a trans fashion, three of which are 
Lymphotoxin, Interleukin-2 (T-cell Growth Factor) and GM-CSF. 

Lymphotoxin, or Tumor Necrosis Factor-6, was previously 
identified to be an activator of osteoclasts70 and was thought to be 
at least one of the Osteoclast Activating Factors (OAFs)l71. The 
production of such OAFs by the TAX gene was especially 
intriguing since many patients who succumbed to T-cell leukemia 
were not victims of the leukemic T-cells per se, but were victims 
of flagrant hypercalcemia consequent to increased bone resorption. 
Such observations have fueled interest in the roles of GM-CSF not 
only in HTLV-l-induced bone resorption but in normal, 
osteoporotic, and Pagetic bone resorption as well. Evans et al. 
reported that recombinant human GM-CSF stimulated osteoblast 
proliferation, but inhibited osteoblast alkaline phosphatase activity 
and 1, 25 (OH)2 vitamin D3-induced osteocalcin synthesis59. 
Additionally, observations that GM-CSF is a growth factor for 
osteosarcoma and acute and chronic myeloid leukemic cells has 
implicated the hormone in neoplastic processes of liquid and 
mineralized tissues as well43’194. Some reports have implicated 
GM-CSF and other colony stimulating factors as inducers of 
cartilage degradation by chondrocytes98. 
GM-CSF and clinical applications. Treatment of 
intrinsic and acquired leukopenias; Limited, yet promising results; 
GM-CSF functions to maintain the biological activity of those 
cells induced by the hormone. That is, GM-CSF not only induces 
granulocytopoesis, it prolongs and enhances neutrophil and 
eosinophil phagocytosis, chemotaxis and antibody-dependent 
cytolysisl37a, and enhances macrophage syntheses of 
prostaglandin E and plasminogen-activators43. Donahue et al. 
showed that continuous infusion of human GM-CSF into Macaca 
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fasicularis and mulatta monkeys induced a five-fold increase in 
white cell counts within 36 hours without toxic effects53a. Later 
experiments showed that GM-CSF infusion could also hasten the 
recovery from marrow transplantation-induced 
pancytopenia53b,170. Laboratory successes prompted the use of 
GM-CSF in clinical trials for patients with myelodysplastic 
syndromesI95, aplastc anemia26’40, and the leukopenia of the 
acquired immunodeficiency syndrome (AIDS)74’75. In one study, 
continuous intravenous infusion GM-CSF daily for two weeks in 
patients with the myelodysplastic syndrome increased granulocyte 
counts 5- to 373-foldl95. Monocytes, eosinophils, and 
lymphocytes also increased. Dramatic increases in circulating 
neutrophils, eosinophils, and monocytes in AIDS patients after GM- 
CSF treatment fell to background 1-2 days after treatment was 
stopped75. Such clinical successes point to both the enourmous 
potential of GM-CSF in medical treatments of hematologic disease, 
as well as the hormone's short course of action. 
E. MACROPHAGE-CSF (M-CSF). Exists as two different forms in 
vivo; M-CSF induces the development of monocyte lines into macrophages. The 
M-CSF receptor is encoded by c-fms. 
M-CSF was the first hematopoetic growth factor identified by 
analysis of spleen cell colony proliferation and was originially called, 
therefore, Colony Stimulating Factor 1 (CSF-l)137b’l92. cDNAs 
for M-CSF were obtained only after the native amino acid sequence 
of the protein was used to predict the nucleotide sequences of 
disparate regions of M-CSF mRNA105. Synthetically produced 
oligonucleotides were then used to identify and eventually isolate a 

complete cDNA for the M-CSF gene. Various cell lines transcribe 
the M-CSF gene into two species of mRNAs, a 1.8 kilobase message 
and a 4.0 kilobase message. The 4.0 kB mRNA is produced after a 










Figure Il.xiii. M-CSF processing. Two forms of active dimeric M-CSF exist, a 45 
and a 85 kDa proteins, both derived from a 1.8 and a 4.0 kb mRNA splice product, 
from the same DNA transcript, respectively. The smaller mRNA differs from the 
larger in that codons for 298 amino acids are inserted between residues 181 and 182 
of the smaller species. There is some evidence that this may occur, in part, post- 
transcriptionally. 
above in figure Il.xiii, the M-CSF mRNAs are post-translationally 
processed into two different species of M-CSF hormone; the 1.8 kb 
mRNA yields a 18-26 kDa protein and the 4.0 kb mRNA codes for a 
35-45 kDa molecule2^. The two proteins are then N-glycosylated 
to attain molecular weights of 45 kDa, and 85 kDa, respectively. 
The two proteins then form dimers with one other molecule of the 
same weight species to yield an active M-CSF hematopoetin. Thus, 
two different forms of the hormone exist in vivo ; a dimer 
consisting of two 45 kDa glycoproteins and another consisting of two 
85 kDa glycoproteins 137a, 
As shown in figure Il.xii, M-CSF induces promonocytes and 
monocytes to differentiate into macrophages. In this respect, M-CSF 
is unlike GM-CSF in that M-CSF affects cell types at relatively late 

stages of maturation. M-CSF also increases macrophage 
cytotoxicity and appears to increase monocyte/macrophage 
longevity43. M-CSF modulates hematopoiesis further by inducing 
production of interferon-gamma and Tumor Necrosis Factor-alpha 
from monocytes200. 
M-CSF is unlike the three other CSFs in that there are 10-50 
times the number of receptors for M-CSF on a given cell than there 
are for GM-CSF, IL-3, or G-CSF25,137b,205,209. The observation 
that the M-CSF receptor, a 165 kDa glycoprotein, is identical to the 
product coded by the proto-oncogene c-fms may implicate abnormal 
transduction of signal by M-CSF receptors in neoplastic growth173. 
M-CSF and bone. M-CSF enhances osteoclast 
proliferation; Op/op mice have osteopetrosis and are homozygous for a defective M- 
CSF gene; Osteopetrosis resolves with M-CSF therapy. 
M-CSF enhances the development of osteoclast 
precursors7715’ 128b,206,212. The finding that osteoblasts produce M- 
CSF in response to PTH and PTHrP suggests further that osteoblasts 
may regulate osteoclast activity via paracrine hormone 
production203. 
Wiktor-Jedrzejczak and coworkers have shown that M-CSF 
may have particular importance in bone cell biology, as illustrated 
by the researcher's study of the bone disease, osteopetrosis. 
Osteopetrosis is a disorder of bone remodeling consequent to a 
profound deficiency of osteoclasts, the bone resorbing cell. 
Children bom with the disease have extremely brittle bones which 
are resistant to normal bone growth. Osteopetrotic children can be 
effectively cured, however, by a successful transplant of bone 
marrow. Normal osteoclasts eventually grow out from monocytic 
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lines in the marrow and repopulate bone matrices throughout the 
body (figure ILxii). To study the disease process further, a mouse 
strain was developed which was homozygous recessive for 
osteopetrosis, the so-called op/op mouse206. Op/op mice are smaller 
than normal littermates, have a lower birth weight, have no teeth, 
and have bones typical of osteopetrosis which are devoid of 
osteoclasts. Because the mice also have low numbers of circulating 
moncytes and macrophages, the M-CSF gene was implicated in the 
disease etiology. Wieslaw-Jedrzejczak et al. eventually 
demonstrated that tissues from op/op mouse were devoid of M-CSF 
whereas op/+ and +/+ littermates had normal levels of the 
hormone206. Furthermore, only the larger 4.6 kB mRNA species 
was detected in op/op mice, whereas normal littermates expressed 
both 2.3 and 4.6 kB species. Eventually, a stop codon was identified 
in the middle of an important reading frame in the op/op mouse 
STOP 
Figure Il.xiv. The wild vs. op/op M-CSF amino acid sequence from residues #54- 
68 of exon 4. An insertional mutation of thymidine in a codon for leucine produces 
a codon translates for serine and produces frameshift mutations distally until a 
TGA stop codon is read producing a truncateded molecule unable to act as a ligand 
for the M-CSF receptor. 
mRNA for M-CSF, an oligonucleotide error which precluded 
production of the hormone (Figure Il.xiv)212. Administration of 
recombinant murine M-CSF replenished osteoclasts in the op/op mice 

and cleared the animals of disease. These experiments demonstrated 
both the importance of a specific hematopoetin in the etiology of a 
particular disease as well as the role such hematopoetins may play in 
normal bone physiology. 
F. Thesis Investigation. 
The discussion of TGF-6 and the cytokines above points to the 
diverse activities of these hormones in cell growth and regulation. 
Many of TGF-B's roles include modulating the effects of other 
growth factors. Mineralized tissue may be unique in this regard 
because bone is not only a large source of active TGF-B but of 
several osteoblast-derived growth factors. Any relationship 
between active TGF-B and the regulation of osteoblast-derived 
cytokine production, however, as not yet been defined. 
Understanding the regulation of osteoblast-derived cytokine 
production may help towards describing the function of these growth 
factors in vivo. 
This thesis presents experiments which tested the affects of 
TGF-B on fetal rat osteoblast production of IL-1, IL-6, GM-CSF, 
and M-CSF, as assayed with known growth factor-dependent cell 
lines. This work presents a novel description of growth factor 
interactions which may have relevance to the paracrine regulation of 
bone remodeling and hematopoesis in vivo. 

m. MATERIALS AND METHODS 
A. Cell Preparation. 
1. Primary cultures of fetal rat osteoblasts. Fetal rat calvaria were 
obtained at 22 days gestation and isolated under sterile conditions. Primary cells 
vvere obtained through a sequential collagenase digestion procedure as detailed by 
Wong and Cohn208# After a 20 minute digestion in 3 ml isotonic salt with 0.1 % 
collagenase, 0.05 % trypsin, and 4mM EDTA at room temperature the first 
eluted cell suspension was saved as population #1. The eluant obtained through a 
second 20 minute digestion was discarded, but the cells recovered from the 3rd, 
4th, and 5th digestions were saved, and pooled, as populations # 3-5. Analysis of 
known cellular markers for osteoblasts (alkaline phosphatase activity, response to 
parathyroid hormone, synthesis of collagen I & III) has previously determined 
that cells from populations #3-5 are predominantly (> 95%) osteoblasts and 
osteoblast precursors"^ As described in III.C.5 and V.ii, osteoblast preparations 
I 
were assayed for interleukin-1 activity (IL-1) to determine the presence of 
contaminating macrophages which constitutively release IL-1. No significant IL- 
1 activity was found in any preparation of osteoblast CM (data not shown). The 
LBRM assay for IL-1 activity can detect IL-1 concentrations down to 10 
pg/ml213b. The absence of detectable IL-1 activity is therefore suggestive that the 
osteoblast preparations were reasonably devoid of macrophage activity (data not 
presented). 
All preparations of primary osteoblast cultures were kindly provided by 
Dr. M. Centrella, St. Francis Hospital, Hartford, Connecticut. 
2. C3H/HeJ mouse bone marrow cells. Total bone marrow cell cultures 
were obtained from a C3H/HeJ mouse (Jackson Laboratories, Maine). The 
animal was killed with cervical dislocation. The two hind legs were cleaned with 

50% ethanol and shaven. The femurs were isolated and removed to a sterile 
field. The metaphyses of each bone were removed and the indwelling marrow 
cells expelled with PBS introduced by a 10 cc syringe. The cells were collected, 
washed three times in PBS and counted. The cells were placed into Costar 
culture plates for experimentation as described in IV. D and maintained in 
Dulbecco's modified Eagles medium (DMEM) with nonessential amino acids, 
penicillin, streptomycin, 20 mM HEPES, 100 ug/ml L-ascorbic acid, and 10 % 
fetal calf serum (FCS). 
All preparations of C3H/HeJ mouse bone marrow cells were made by the 
author. 
B. Preparation of Conditioned Medium (CM). Cells suspensions were 
plated out in 6 well tissue culture plates (Costar) at a concentration of 5 x 10^ 
cells/well, and grown in Dulbecco's modified Eagles medium (DMEM) with 
nonessential amino acids, penicillin, streptomycin, 20 mM HEPES, 100 ug/ml L- 
ascorbic acid, and 10 % fetal calf serum (FCS). Cells were cultured in the serum 
containing media until the cells reached sub-confluence, at which time the media 
was withdrawn, the cells washed twice in phosphate buffered saline (PBS), and 
serum-free media added to the culture wells. The cells were maintained in the 
serum-free media 60-72 hours until confluent. The media was removed, the 
cells washed twice with PBS, and fresh serum-free media was returned to the 
wells along with the appropriate inducing agents for each experimental protocol 
as noted in the text. A typical experiment maintained the cell monolayers for 48 
hours at 37°C in 5% C02- Following the culture period, the CM was collected, 
filtered through Millipore symige-held membranes, and frozen at -20.C. 
A series of 'priming' experiments are described and presented in sections 
IV. v and xv and were conducted as follows: Confluent, serum-deprived cells 
were exposed to a single agent in serum-free media for a 2 hour time period. 

The cells were then washed twice with PBS and a second agent was then provided 
to the cells in fresh serum-free media for 46 hours. The supernatant was then 
removed and saved as a CM and analyzed for cytokine activity as described below 
in sections IV. v and xvi. Appropriate control CMs were obtained for each 
experiment. For example, if a cell group was exposed to TGF-13 for 0-2 hours 
and then LPS for 2-48 hours, the three experimental controls would include (1) 
CM from cells exposed to serum-free media for 0-2 hours and again for hours 2- 
48, (2) CM from cells exposed to TGF-6 for 0-2 hours and then to serum-free 
media alone for 2-48 hours, and (3) CM from cells exposed to serum-free media 
alone for 0-2 hours and then to LPS for 2-48 hours. 
A series of 'time course' experiments were conducted in which confluent 
osteoblasts were prepared as described above and then treated with indicated 
agents in fresh serum-free media. Conditioned media was then removed and 
saved for later analysis after 6, 22 and 48 hours of treatment. A second 
experiment used the same protocol but analyzed CMs removed after 1, 2.5 and 6 
hours of treatment. 
All CMs were prepared by Drs. M. Centrella and T. McCarthy, St. Francis 
Hospital, Hartford, Connecticut unless otherwise specified in section IV. 
C. Cytokine Assays. 
1. Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF). GM- 
CSF activity was determined using the HT-2 T-cell assay as was initially reported 
by Kupper et al.116b. Briefly, as outlined in table Ill.i below, HT-2 cells were 
maintained in suspension in continuous culture in Eagles Hanks Amino Acid 
(EHAA) medium with 10% fetal bovine serum (FBS), penicillin, and 
streptomycin. Cells were washed three times in phosphate buffered saline (PBS) 
(Gibco, Grand Island, N.Y.) with 2% FBS, resuspended in EHAA with 10% FBS, 
and plated into wells of 96 well tissue culture plates (Costar) at a concentration of 
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2 x 1()4 cells/well. Varying concentrations of test CM were added to the cells. A 
final volume of 200 pi was achieved with complete media. Triplicate cultures 
were incubated for 48 hours at 37 °C in 5% CO2. HT-2 cells proliferate in 
response to GM-CSF as well as Interleukin-2 (IL-2). Recombinant human 
interleukin-2 (r-hu IL-2) is, therefore, used as a positive control in the HT-2 
assay. 
HT-2 cells respond to GM-CSF, IL-2, and IL-4H6c. IL-2 and IL-4 activity 
has never been identified in the preparations of osteoblasts used in the these 
present studies (M. Horowitz, unpublished). Osteoblasts do not produce IL-2 
suggesting that HT-2 cell-inducing activity in a given CM is due to the presence 
of GM-CSF. To test for the presence of GM-CSF in a given CM, a goat 
antibody against rat GM-CSF was used at a concentration of 1:1000 in assays as 
specified in section IV. iv. The antibody was made and provided by Dr. J. 
b) 
J 
Figure IEI.i. Preparation of conditioned media, a) Parietal bones dissected from fetal rat pups at 
22 days gestation, b) Bones digested with .1% collagenase to obtain populations of osteoblasts, c) 
Osteoblasts grown to confluence and serum-deprived for 24 hours, d) Reagents added to cultures 
for given time interval, e) Supernatants collected as conditioned media (CM). 

Schreurs, DNAX (Palo Alto, California). The antibody preparation against GM- 
CSF does not cross-react with IL-2, IL-3, G-CSF, M-CSF, or any other known 
cytokine (J. Schreurs, unpublished). 
HT-2 cells were grown for 44 hours, pulsed with 1 p.Ci/well of ^H- 
Thymidine (Specific Activity: 70-85 Ci/mmol) (New England Nuclear, 
Cambridge, Mass.) and harvested at 48 hours onto glass fiber filters using an 
automated sample harvester (Cambridge Technologies, Cambridge, Mass.). 
Incorporated radioactivity was measured with a Beckman scintillation 
spectrometer (Fullerton, Ca.). Data are presented as the mean of the triplicate 
cultures ± the standard error (SE). All data presented are representative of 
multiple experiments. All assays for GM-CSF were made by the author. 
2. Interleukin 6 (IL-6). IL-6 activity was determined using the IL-6 
dependent hybridoma developed by Aarden et al. and Landsorp et al. known as B 
13.29, or the subclone, B-91’121. B-9 cells are 15-20% more sensitive than the B 
13.29 parent line to Hybridoma Growth Factor (HGF) as assayed by Aarden et 
ail, 121 B-9 ceps win proliferate in response to a minimum of .06-. 125 
units/ml HGF (IL-6) and maximally respond to ~2 units/ml HGF (IL-6)1. The 
cell line does not proliferate in response to other cytokines and is presumed IL-6 
dependent1’!2!. B-9 cells were maintained in EHAA medium, penicillin, 
streptomycin, glutamine, and 2% FBS. The cells were washed three times in PBS 
with 2% FBS, resuspended in EHAA with 2% FBS, and plated in 96-well tissue 
culture plates at a concentration of 104 cells/well. Varying concentrations of test 
CM were added to the cells, and a positive control was established using the 
supernatant from the human bladder carcinoma cell line, T24. Cells were grown 
for 56 hours and then pulsed with 1 jiCi/well of ^H-Thymidine (Specific Activity: 
3-4 Ci/mmol) (New England Nuclear, Cambridge, Mass.) and harvested at 72 
hours with an automated sample harvester (Cambridge Technologies, Cambridge, 

Mass.), and measured for radioactivity with a Beckman scintillation spectrometer 
(Fullerton, Ca.). Data was presented as the mean of each triplicate ± the SE. 
A monoclonal mouse antibody against IL-6 was prepared by Lansdorp et 
al.121. The antibody was used in experiments to block the activity of CMs which 
had B-9 cell inducing activity. The antibody failed to block the activity of CMs 
over a broad range of concentrations and there was some evidence that the 
antibody preparation itself was stimulatory for B-9 cells (data not presented). 
The presence of IL-6 in given CMs could not be thus confirmed. However, the 
specificity of B-9 cells for IL-6-dependent growth is highly suggestive that the 
activity of a given CM is due to IL-6. In subsequent experiments the stimulatory 
activity of the CM was confirmed using a second neutralizing anti-IL-6-antibody 
(M. Horowitz, pers. comm.). 
All assays for IL-6 were made by the author. 
3. Macrophage Colony Stimulating Factor (M-CSF). M-CSF activity was 
determined using the growth factor dependent macrophage cell line, BAC 
1.2F5139b,184 Morgan reported that BAC cells proliferate in response to a 
minimum of 50-100 units/ml CSF-1 (M-CSF) with >98% viability and maximally 
proliferate in response to -3000 units/ml CSF-1. BAC cells have not been shown 
to proliferate in response to other cytokines except M-CSF139b BAC 1.2F5 cells 
were maintained in Iscoves medium supplemented with 10% FBS and 10% L929 
cell CM as a source of M-CSF. Cells were washed in PBS and plated into 96 well 
tissue culture plates at a final concentration of 1 X 10^ cells/well. Varying 
amounts of CM were added to each well. The cells were cultured for a total of 
72 hours, pulsed with 1 jiCi/well of 3H-Thymidine (3-4 Ci/mmol specific 
activity) for the last 16 hours of culture. BAC cells are adherent and were 
therefore prepared for harvesting by discarding the cell supernatants, and 
washing each well twice with 50 p.l/well of PBS. Cells were swollen open by the 
addition of 50 pl/well of H20, incubated for five minutes, and then by the 

addition of 50 jllI of 1 N NaOH for five minutes. Lysate from each well was then 
harvested onto glass fiber filters using an automated sample harvester 
(Cambridge Technologies, Cambridge, Mass.). Radioactivity was measured using 
a Beckman scintillation spectrometer (Fullerton, Ca.), and the data was presented 
as the mean ± the SE of each triplicate. 
All assays for M-CSF were made by the author. 
4. Interleukin-1 (IL-1). IL-1 activity was determined using the LBRM 
33-1 A5.47 (LBRM) T-cell lymphoma and CTLL-2/CT-6 (CTLL) T-cell 
lines212b. Zlotkin et al. originally reported that LBRM cells proliferate 
maximally to co-stimulation by IL-1 (25% supernatant from P388 D1 SN 
macrophages, a DBA/2-derived tumor line, Amer. Type Cult. Collec.) and 
phytohemagglutiinn (PHA) (50 jj,g/ml)2113b, The LBRM cells produce a 
maximum of 640 units/ml Interleukin-2 (IL-2) in response213b One unit of IL-2 
is defined as the minimum dilution of CM capable of achieving 90% viability of 
4000 HT-2 cells for 24 hours212b. 
The LBRM assay for IL-1 activity is performed in two parts: First, the 
IL-1 responsive T-cell lymphoma cell line LBRM 33-1A5.47 is cultured in the 
presence of osteoblast-derived CMs. After 12 hours the supernatants are 
removed and filtered. Second, the CTLL-2/CT-6 T-cell line is then cultured with 
the filtered CMs. The LBRM cells produce IL-2 in response to any IL-1 in the 
test CMs. The CTLL cells proliferate in response to the IL-2 in the supernatants 
derived from the LBRM cell culture. CTLL cells also respond to high 
concentartions of IL-4 which LBRM cells have not be shown to produce213b. 
LBRM cells are maintained in EHAA with 10 % FBS. The cells were 
washed in PBS three times and resuspended in 96 well tissue culture plates with 
the CMs at varying dilutions. The cells were cultured for 12 hours in the 
presence of phytohaemagglutin (PHA) at 1:200 final concentration. 
Recombinant IL-1 was included as a positive control. At 48 hours, the wells 

were mixed, and the plates were spun at 1500 r.p.m. for 3 minutes to pellet cells. 
50 pi from each well was removed and placed into wells of a 96 well plate, with 
CTLL cells plated at a concentration of 2 x 10^ cells/well. The CTLL cells were 
cultured for 44 hours and then pulsed with ^H-Thymidine (spec, activ. 70-85 
Ci/mmol) for a final 4 hours, harvested with an automated sample harvester onto 
glass fiber filters (both Cambridge Technologies, Cambridge, Mass.), and 
radioactivity was measured using a Beckman scintillation spectrometer 
(Fullerton, Ca.). 
All assays for IL-1 were made by the author. 
TABLE IH.i 
CYTOKINE GM-CSF IL-6 M-CSF IL-1 
ASSAY CELL HT-2 B-9 BAC LBRM/ 
CELL TYPE T-CELL Hybridoma Macr. 
CTLL 
Macr./T-cell 
MEDIA EHAA EHAA ISCOVE RPMI/EHAA 
ASSAY TIME (hours) 48 72 72 12/48 
PULSE TIME (hours) 4 16 16 -/4 
POSITIVE 
CONTROL IL-2 T24 L929 IL-1/2 
D. RNA Analavsis 
1. RNA isolation. Total cellular ribonucleic acid was isolated according to 
the procedures of Chirgwin et alA^b. Briefly, confluent monolayers of 
osteoblasts were lysed with a guanidinium lyze buffer (GTC) [4 M Guanidine 
Thiocyanate (American Bioanalytical), 0.5 % NaN-lauryl sarcosine (Sigma), 1 M 
Na Citrate, pH 7.0, 0.7 % v/v 2-mercaptoethanol, and 0.33% v/v 30% anti-foam 

A (Sigma), all Millipore-filtered three times and stored at 4° Cj. Lysate was 
drawn into a 10 ml syringe through a 23-gauge needle to shear DNA:DNA 
hybrids. Sheared lysate was then layered on top of a 3 ml 5.7 M Cesium 
Chloride solution (Gallard-Schlesinger Ind.), with 25 mM Na Citrate, pH 5, in a 
15 ml SW 41 polyallomer tube (Beckman). Tubes were then topped off with 
guanidinium lyse buffer. Tubes were centrifuged in a SW 41 rotor for 20 hours 
at 35,000 r.p.m. at 20° C. Supernatant was removed and discarded leaving a 
clear pellet of crude RNA. Pellet was resuspended in 400 pi of 
Diethylpyrocarbonate-treated (500 pg/ml) (Sigma) H2O, and 1/10 volume 4 M 
NaCl was added. The solution was transferred to micro-centrifuge tubes and 
RNA extracted with an equal volume of water-saturated phenol. The acqueous 
(upper) layer was removed and placed into a new micro-centrifuge tube. 2.5 
volumes of cold 100% ethanol was added to tubes and solution was frozen on dry 
ice (-70° C). Tubes were spun for 20 minutes in a microcentrifuge, and the 
supernatant was withdrawn and discarded. Procedure was repeated to resuspend 
and rextract RNA a second time to rid RNA of any residual cesium chloride. 
After a second extraction, RNA was resuspended in 50 pi of DEP'd H20, 1:1000 
dilutions of 1 pi aliquots from each sample were made to test for optical density 
at wave lengths of 260 and 280 nm using a Spectronic 601 spectrophotometer 
(Milton Ray Company). For RNA, 1.0 units of OD at 260 nm corresponded to 
40 pg/ml of RNA. A ratio of 0D 260/280 approaching 2.0 indicated reasonable 
purity of RNA preperation. RNA samples were prepared by the author and 
Andrea Fields, Yale University. 
2. RNA electrophoresis. RNA preparations were brought to concentrations 
of 2 mg/ml. 10 pi (20 pg) of RNA was then mixed with 20 pi of glyoxal buffer 
[1 M glyoxal (Eastman Kodak), 0.1 % SDS (Boehringer-Mannheim), 10 mM 
Phosphate buffer (pH 6.8 mono/dibasic), 50 % vol/vol Spectrograde DMSO, 
brought to volume with DEP'd H20] and incubated at 50° C for one hour. 15 pi 

(10 jig) RNA was loaded into each lane of a 1.5 % agaorse gel made up in 10 mM 
Phosphate buffer, and was electrophoresed into the gel matrix body at 0.5 
volts/cm. Once the RNA front was in the body of the gel, the voltage was 
increased to 5 volts/cm until the gel front had traversed at least 60 % of the gel 
length. The elctrophoresis was then stopped. Electrophoresis was performed by 
the author and Andrea Fields, Yale University. 
3. Northern blotting. After electrophoresis, gel was removed and placed 
upside down on an ethanol/0.3 % H2O2 cleansed industrial sponge soaked in a pan 
of 20 X SSC (3M NaCl, 0.3M Na citrate, pH 7.0). A square of Zeta bind 
(Amersham) blotting paper was cut to fit the gel, was soaked in H2O one minute 
to wet, and was placed onto the gel. A pipette was used to force out bubbles 
between blot and gel interface. A piece of filter paper (Whatman) of the same 
proportions as the gel was wetted in H2O and placed on the blotting paper 
followed by five similar but dry pieces of filter paper. Two Diaper-liners 
(Johnson & Johnson) were then placed on top of the filter paper, and a plastic 
plate placed on top of liners. A 500 gm bottle was placed on plate as a weight. 
The apparatus was left in place for 15-20 hours and then the Zeta-bind was 
removed, and briefly rinsed for 15 seconds in 2X SSC and then let dry for 10 
minutes. Blotted RNA was cross-linked with a hand-held short-wave ultraviolet 
light source for 3 minutes. Hybrization was performed by the author and Andrea 
Fields, Yale University. 
4. Radiolabeling of cDNA IL-1R probes. Probes of complimentary DNA 
(cDNA) for murine IL-1R were labeled with 32p_ATP/CTP by random priming 
of a IL-1R insert. The IL-1R cDNA was carried in a pGEM-2 vector and was 
kindly provided by Simone Carding, Yale University. The IL-1R 300kb insert 
was prepared and radiolabeled by Andrea Fields, Yale University after double 
digestion with ECOR1 and Pstl for 30 minutes at 37° C. The fragment was 




using the Random Priming kit (Boehringer-Mannheim) protocol. Briefly, the 
linear piece of cDNA was denatured by boiling for 5 minutes, and 50 ng of 
cDNA was placed in a 1.5 ml tube. To this was added 1 pi each of dGTP and 
dTTP (50 mM stcok), 2 pi reaction buffer ("hexanucleotide mixture in 10 x 
concentrated reaction buffer"), 50 pCi each of 32P dCTP and 32p dATP (New 
England Nuclear), and 1 pi of Klenow fragment (2 u/pl). The mixture was 
placed in a 37.0 °C water bath for 30 minutes. A second 1 pi of Klenow (2 u/pl) 
was added to the reaction and the reaction was left overnight at room temperature 
(22.5° C). The reaction was stopped with enough kit stop buffer to increase 
reaction volume to 100 pi. Radio-labeled cDNA was isolated after passing 
mixture over a Sephadex G-50 spin-column centrifuged at 1500 r.p.m. for 5 
minutes. 
5. Hybridization. Filters were pre-hybridized for 30 minutes at 65° C in 
10 mis of 1% Bovine Serum Albumin (Fraction V, Sigma), 7% Sodium 
Dodecyl Sulfate (Boehringer-Mannheim), 500 mM Sodium Phopshate buffer, 
and 25 mM EDTA, all sealed in a Seal-a-meal® bag. Radionucleotide-labeled 
probe was added at 1-10 x 106 cpm/ml and hybridized for 15-20 hours at 65° C. 
Following hybridization, fluid was drained and disposed and blot was washed 
twice in 65° C Wash buffer A (5% SDS, 0.5 % BSA, 50 mM Sodium Phosphate 
Buffer, 2.5 mM EDTA) and then twice in buffer A for 15 minutes at 65° C each. 
A second buffer of 1% SDS, 50 mM Sodium Phosphate buffer, and 2.5 
mM EDTA (Wash B) was used to wash the blot three more times at 65° C. Blot 
was then briefly dried by blotting with Kim-wipes and then placed in an envelope 
of saran wrap. Biot was placed in an X-ray exposure holder (Kodak) and 
covered with one piece of X-OMAT AR type film (Kodak). An intensifying 
screen (Parker X-ray) was placed on film and holder was sealed, and placed in a 
70° C freezer until exposure time as noted in the text. 
Hybridization was performed by the author and Andrea Fields, Yale University. 

IV. RESULTS 
STUDIES OF GM-CSF: TGF-B and LPS 
IV.i. TGF-B does not induce the release of GM-CSF. To determine 
whether TGF-B could induce GM-CSF release from osteoblasts, various 
concentrations of TGF-B were added to serum-deprived osteoblasts. As 
described in III.B, the conditioned media (CM) was collected after 48 
hours and tested for GM-CSF activity with the T-cell line HT-2. As 
presented in figure IV.i, 0.1-10 ng/ml of TGF-B did not induce GM-CSF 
activity in various dilutions of tested CMs, compared to both experimental 
controls (no TGF-B) and to assay controls (no tested CM). 
rhulL-2 
Figure IV.i. HT-2 cell assay for TGF-B-induced GM-CSF activity in test CMs. Included 
are negative test controls (no TGF-B), positive assay controls (recombinant human 
Interleukin-2), and negative assay controls (no CM). 

IV.ii. Lipopolvsaccharide (LPS) induction of GM-CSF release is dose- 
dependent. Although 10 pg/ml of LPS had been known to induce GM-CSF 
release from osteoblasts, the effect of lower doses of LPS on osteoblasts 
was unclear. As described in III.B, serum-deprived osteoblasts were 
exposed to LPS at concentrations of 10 ng/ml to 10 pg/ml for 48 hours. 
CMs were tested for GM-CSF activity using the HT-2 T-cell assay. As 
shown in figure IV.ii below, LPS, at concentrations greater than 1.0 pg/ml, 
induced considerable GM-CSF activity whereas LPS at concentrations less 
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Figure IV.ii. HT-2 assay for GM-CSF activity of CMs from osteoblasts cultured with 
different concentrations of lipopolysaccharide (LPS). Included are a test control (no LPS), 
a negative assay control (no CM), and a positive assay control (recombinant human IL-2). 
IV.iii. TGF-B and low dose LPS svnergize for release of GM-CSF from 
osteoblasts. From the previous experiment, it had been determined that 

neither 10 ng/ml of TGF-B nor LPS at concentrations < 100 ng/ml induced 
GM-CSF release from osteoblasts. To test whether TGF-B would change 
the response of osteoblasts to sub-stimulatory levels of LPS (<100 ng/ml), 
osteoblasts were exposed to either TGF-B alone, to substimulatory LPS 
alone (10 or 100 ng/ml), or to TGF-B (10 ng/ml) together with LPS (10 or 
100 ng/ml). As presented in figure IV.iii below, neither TGF-B alone nor 
LPS alone induced GM-CSF activity in CMs. However, TGF-B combined 
with LPS synergized to induce a substantial increase in GM-CSF activity. 
Figure IV.iii. HT-2 assay for GM-CSF activity of CMs from osteoblasts cultured with 
either TGF-B alone or with LPS alone, or with TGF-B and LPS together. Included are a 
negative assay control (no CM) and a positive assay control (10% rhIL-2). 1=LPS at 10 
ng/ml, 2=LPS at 100 ng/ml, 3=TGF-B at 10 ng/ml, 4= LPS at 10 ng/ml + TGF-B at 10 
ng/ml, 5=LPS at 100 ng/ml + TGF-B at 10 ng/ml. a=2.5% CM, b=5% CM, and c=10% 
CM. 10% negative experimental control CM (no agents) induced 1.8 x 103 3H-TdR cpm. 

IV.iv. TGF-B/LPS-induced GM-CSF activity in tested CMs can be 
neutralized with goat antibody against mouse GM-CSF. To determine 
whether the observed increases in GM-CSF activity of CMs, as presented in 
figure IV.iii, was specifically due to GM-CSF, the same CMs were re¬ 
tested in the HT-2 assay with either supplemental goat antibody to mouse 
3HTdR cpm x 1 
Figure IV.iv. HT-2 assay for GM-CSF activity of 10% CMs co-cultured with either heat- 
inactivated goat serum or goat antibody to mouse GM-CSF. Slashed histograms represent 
samples assayed in the presence of a 1:1000 dilution of the goat antibofy and the clear 
histograms represent samples assayed in the presence of a 1:1000 dilution of the inactivated 
serum. Background controls include normal goat serum alone (NGS) and goat anti-mouse 
GM-CSF alone ( GM-CSF). Other controls not presented include 10% recombinant 
human IL-2 (42450 ±320 cpm) and assay background activity (450 ± 35 cpm). Standard 
deviations are also represented. 
GM-CSF or with heat-inactivated normal goat serum. As shown in figure 
IV.iv above, the TGF-B /LPS-induced increase in GM-CSF activity was 
blocked to within background levels by goat anti-mouse GM-CSF but not 
by normal heat-inactivated goat serum. 

IV.v. TGF-B/LPS svnergv for GM-CSF release is TGF-B dependent. As 
described in III. B, a series of 'priming' experiments were conducted in 
which osteoblasts were exposed to either TGF-B alone for two hours, or to 
low-dose LPS alone for two hours. The cells were then washed, and then 
incubated with the complementary synergen for the next 46 hours (Cells 
incubated with TGF-B for hours 0-2 were exposed to LPS for hours 2-48). 
As shown below in figure IV.v., there was no GM-CSF activity in CMs 
from cells cultured with LPS alone for hours 0-2 and then with TGF-B for 
0-2 hrs 
TGFp 400 pM 
TGFp 400 pM 
TGFp 400 pM 
LPS 1 pg/ml 
LPS 100 pg/ml 
LPS 1 pg/ml 
LPS 100 pg/ml 
3FITdR cpm x 10 3 
Figure IV.v. HT-2 assay for GM-CSF activity in 10% CMs from osteoblasts 'primed' 
with either TGF-B or with LPS and then exposed to the corresponding synergen. Included 
are negative (assay cells) and positive assay controls (10% rhEL-2) as described above. 

hours 2-48. However, cells incubated with TGF-B for hours 0-2, and then 
LPS for hours 2-48 produced CMs with the high GM-CSF activity seen in 
previous experiments. 
IV.vi.a/b. Most of the TGF-B/LPS-induced release of GM-CSF occurs 
between hours 2.5 and 6. TGF-B and LPS induced large increases in GM- 
CSF activity of CMs after 48 hours of cell treatment, as described above. 
To decribe a more complete spectrum of activity, two experiments were 
conducted. In the first (IV.vi.a.), CMs were collected at hours 0, 6, 22, 
and 24 and analyzed for GM-CSF activity while the second (IV.vi.b) 
analyzed CMs collected at hours 0, 1, 2.5, and 6.0. As shown below in 
figure IV.vi.a. below, CMs at time zero (CMs collected before addition of 
agents to media) contained no detectable GM-CSF activity compared to 
Figure IV.vi.a. HT-2 assay for GM-CSF activity of indicated 10% CMs. Values not 
included are the assay control (850 ± 20), experimental negative control [no agents] (920 ± 













background samples. CMs at six hours of incubation contained ten to 
twenty times the GM-CSF activity of relevant background samples. CMs at 
22 hours incubation contained 15% more activity than 6 hour CMs, and 
CMs at 48 hours contained 20% more activity than CMs at 22 hours. LPS 
as a single agent induced a small increase in GM-CSF activity in six hour 
CMs, but the level of activity plateaued over the next 42 hours. The second 
experiment, presented as figure IV.vi.b below, tested CMs at hours 0, 1, 
2.5, and 6 to determine GM-CSF release at earlier time points than 
discussed in IV.vi.a. As shown below, no GM-CSF activity was detected in 
the zero, 1, or 2.5 hour CMs. The 6 hour CMs contained the high GM-CSF 
Figure IV.vi.b. HT-2 assay for GM-CSF release over hours 0-1, 1-2.5, and 2.5-6. 
Histograms represent the GM-CSF activity for each 10% CM grouped according to time 
points._l=Control, 2=LPS at 10 ng/ml, 3=TGF-B at 10 ng/ml, 4=2+3. Positive assay 
control of 10% rec. human IL-2 induced 69,000 ± 550 cpm in HT-2 cells, while a negative 
assay control of assay cells alone yielded 650 ± 40 cpm. 

activity levels observed previously. The data from IV.vi. a and b suggest 
that the effect of TGF-6 and LPS on osteoblasts for GM-CSF release is 
obtained after a minimum of 2.5 hours of exposure to the synergens, 
maximizes quickly, and is short-lived. 
IV.vii. The rate of GM-CSF release is at a maximum between hours 0-6. a 
rate 95% higher than the rate of release between hours 6 & 22 and between 
22 & 48. 
As presented in IV.vi.a, the largest increase in GM-CSF release occurs 
between hours 0 and 6, while smaller increases occur over the subsequent 
42 hours. This difference is presented in figure IV. vii as the rates of 
change in GM-CSF release. As illustrated below, TGF-B and LPS induce 
an increase in the rate of GM-CSF release to a maximum between hours 




Figure IV.vii. Rates of change in GM-CSF release in cells exposed to TGF-B and LPS for 
different intervals of time. The incorporated radioactvity in HT-2 cells induced by a given 
sample of CM is quantitated as counts per minute (cpm). The increase in cpm value 
(Acpm) is divided by the time interval in which a given CM was produced (Atime), either 
6 hours, 22 hours, or 48 hours. The ratio of the cpm value of a given CM to the time 




levels statistically equivalent to background. Finally, the rate of GM-CSF 
release over hours 22-48 remains unchanged from the 6-22 hour release 
rate and is essentially background. 
STUDIES OF GM-CSF: TGF-B and PTH 
IV.viii. PTH alone does not induce GM-CSF release: PTH > 20nM is a 
poor inducer of GM-CSF release in combination with TGF-B. Cells were 
cultured with one of four concentrations of parathyroid hormone (.02, .2, 
2.0 or 20.0 nM). Additionally, some cells were also incubated with TGF-B 
at 10 ng/ml (400 picomolar [pM]). CMs were collected after 48 hours 
incubation and assayed for GM-CSF. As presented in figure IV.viii below, 
PTH alone (at any concentration) did not induce significant GM-CSF 
release. FGF-B also failed to increase cytokine release. Only PTH at a 
concentration of 20.0 nM, when combined with 400 pM TGF-B, induced a 
significant increase in GM-CSF release. 
0 C PTH .02 .20 2.00 20.00 - .02 .20 2.00 20.00 
TGF-P — — - - .40 .40 .40 .40 .40 
Figure IV viii. HT-2 assay for GM-CSF activity of 10% CMs from cells cultured with .02 
- 20 nM parathyroid hormone (PTH) alone or with PTH and TGF-B, as indicated. The 
assay control (no CM) value was 6275 ± 340, the positive control ( 10% recombinant 
human IL-2) value was 32,575 ± 965. 

STUDIES OF GM-CSF: TGF-B and Interleukin-1 
TV. ix. Low-dose Interleukin-1 alone does not induce GM-CSF release, but 
low-dose IL-1 svnergizes with TGF-B to induce a 15-fold increase in GM- 
CSF release. 
It was previously known that concentrations of Interleukin-1 (IL-1) greater 
than 10 pg/ml induced GM-CSF release from osteoblasts (data not shown), 
but the effects of lower doses was unclear. To test low-dose IL-1, and 
whether TGF-B could effect IL-1 action, cells were incubated in either 1, 
10 or 100 nanogram (ng) IL-1. Other cells were also exposed to 10 ng/ml 
TGF-B (400 pM). After 48 hours of incubation, CMs were collected and 
tested for GM-CSF activity. As presented in figure IV.ix, neither 1 or 10 
ng/ml IL-1 induced any significant GM-CSF activity in the tested CMs. 
3HTdR cpm x 10"3 
Figure IV.ix. HT-2 assay for GM-CSF activity of CMs from cells cultured with IL-1 alone 
(1, 10 or 100 ng/ml) or EL-1 with TGF-B (10 ng/ml [400 pM]). Experimental control no 
agents) included. Assay controls: HT-2 cells alone=3; 10% rhIL-2=78. 

Both concentrations of IL-1, however, synergized with TGF-B to produce a 
large increase in GM-CSF activity in tested CMs. 
IV.x. IL-l/TGF-B svnergv is unchanged bv indomethacin. As described in 
III. B, osteoblasts in vitro were exposed to either TGF-B alone or to low- 
dose IL-1 alone or to both agents together. Additional cells were similarly 
cultured but with the addition of the non-steroidal anti-inflammatory agent 
Figure IV.x. HT-2 assay for GM-CSF activity in a series of cyclooygenase inhibition 
experiments with lO-6 M indomethacin. Agents were added to cell cultures for the period of 
time as indicated. Relevant controls are represented as above. Negative assay control 
(assay cells alone) induced 7 x 103 3H TdR cpm activity in HT-2 cells while the positive 
assay control (10% rhIL-2) induced 68 x 103 3H TdR cpm activity. CMs at 10% dilution. 

indomethacin at a concentration of lO6 M. As shown above in figure 
IV.x, there was no GM-CSF activity in CMs from cells cultured with the 
IL-1 alone or with TGF-B alone. As expected, TGF-B and IL-1 synergized 
to increase GM-CSF release greater than 10 fold. The addition of 10~6 M 
indomethacin to the cultures did not change the GM-CSF release response 
of the osteoblasts cultured with either IL-1 or TGF-B alone. There was a 
slight (<5%) increase in the GM-CSF released by osteoblasts cultured with 
all three agents (IL-1, TGF-B, and indomethacin). 
IV.xi. Maximum GM-CSF release by TGF-B/IL-1 synergy is achieved 
between hours 2.5 and 6 of stimulation, is rapid, and short-lived. As 
discussed above in IV.vi a and b regarding the time-course of TGF-B/LPS 
synergy, the time-course for TGF-B/IL-1 synergy was determined by 
analyzing CMs for GM-CSF activity obtained at 0, 1, 2.5, and 6 hours of 
exposure to TGF-B alone, IL-1 alone, or to both agents together. As 
presented in figure IV.xi below, no or little GM-CSF activity was 
observed in CMs at hours 0, 1, or 2.5. CMs collected at 6 hours of 
exposure to both TGF-B and IL-1, however, contained 30 times the activity 
of control samples. Although not included below, CMs obtained at 6, 22, 
and 48 hours were also tested for GM-CSF activity. Similar to the results 
of experiment IV.vi.a above concerning TGF-B with LPS, CMs from hours 
22 and 48 showed less than 5% more GM-CSF activity than CMs at hour 6 
(not shown). The data of IV.vi a/b (TGF-B + LPS) and IV.xi (TGF-B + 
IL-1) suggest that TGF-B synergizes with LPS or with IL-1 to induce GM- 
CSF release from osteoblasts. The effect occurs after 2.5 hours of 

treatment, peaks after about 6 hours of treatment, and declines dramatically 
soon thereafter. 
Figure IV.xi. HT-2 assay for GM-CSF activity in 10% CMs collected at specified time 
points, grouped as histograms. l=Control, 2=IL-1 10 ng/ml, 3=TGF-B at 10 ng/ml, and 
4=2+3. Positive control of 10 % recombinant human IL-2 induced 69,000 ± 550 cpm and 
an assay background control was 620 ± 40 cpm. 
IV.xii. TGF-B increases mRNA levels for the interleukin-1 receptor. To 
determine the effect of TGF-B, LPS, and IL-1 on osteoblast mRNA 
production, osteoblasts were cultured with 10 ng/ml TGF-B alone, 10 
ng/ml IL-1, 10 ng/ml LPS alone, TGF-B + IL-1 (each at 10 ng/ml), or 
TGF-B -r ^PS (each at 10 ng/ml). According to the procedures outlined in 
m.D.1-5, samples of mRNA from each treatment group were obtained. 10 
jig RNA from each sample were electrophoresed , transferred to 
nitrocellulose membranes, and hybridized with 32p_iabeled linear cDNA 
for the interleukin-1 cell surface receptor (IL-1R). The autoradiograph 

obtained, as presented below in figure IV.xii, indicate that TGF-B may 
increase the amount of intracellular mRNA for the IL-1R. IL-1 had no 
effect, nor did the synergen increase the amount of IL-1R mRNA when 
combined with TGF-B. LPS also had no effect. The data does not indicate 
whether TGF-B increases mRNA production or message stability. The data 
suggests, however, that the synergy between TGF-B and IL-1 for GM-CSF 
release may be achieved, in part, by a TGF-B-mediated upregulation of cell 
surface receptors for IL-1. 
It 
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Figure IV.xii. Effect of TGF-B, IL-1, LPS, TGF-B + IL-1, and TGF-6 + LPS on IL-1 
cell surface receptor mRNA levels. 48 hour autoradiograph of mRNA hybridization with a 
32P-labeled (random primed) linear strand of cDNA for the IL-1R. Precisely 10 pig of 
RNA was electrophoresed in each lane and hybridized with 5-10 x 106 counts/ml of cDNA 
probe. l=control, 2=IL-1 10 ng/ml, 3=LPS 10 ng/ml, 4=TGF-B 10 ng/ml, 5=2+4, 
6=3+4,7=transformed osteoblast line MC3T3 positive control, 8=resting D-10 T-cell 
mRNA, 9=IL-1 (10'7)/ConA (2.5 pg/ml)-stimulated D-10 positive control. A 
hybridization control with an unrelated probe was not prepared from this blot. The 
specificity of the IL-1R cDNA in previous experiments (data not shown), however, 
suggests that the bands represented above are those of the IL-1R. Blot prepared by A. 
Fields, Yale University. 

A. STUDIES OF INTERLEUKIN-6: TGF-6 and LPS 
IV.xiii.TGF-B induces IL-6 release. Osteoblasts were cultured with 10.0 
ng/ml of TGF-B for 48 hours. CMs were collected and assayed for IL-6 
activity as described in III.C ii. As shown below in figure IV. xiii, 10 
ng/ml TGF-B induced IL-6 activity in dilutions of tested CMs. Similar 
increases in IL-6 activity were observed in repeat experiments, although 
the absolute level of IL-6 activity induced by 10 ng/ml TGF-B varied (data 
not presented). These findings are in marked contrast to the results of 
figures IV.i and iii which show that TGF-B has no effect on GM-CSF 
activity in tested CMs. 
Figure IV.xiii. B-9 assay for EL-6 activity of CMs collected from cells incubated with 
different concentrations of TGF-B. Negative (0) and positive (+C) controls (media alone 
and 1.0% T24 CM, respectively) are included as indicated. Ordinate values are presented 















IV.xiv. IL-6 release is induced bv LPS at concentrations greater than 103 
ng/ml. Cells were incubated with LPS at concentrations of 0.1 ng/ml 1.0 
ng/ml, 100 ng/ml and in a second experiment, of 103 ng/ml or 104 ng/ml 
for 48 hours. CMs were collected and assayed for IL-6 activity using the 
B-9 B-cell hybridoma line as descibed in III.C ii. The experiments are 
presented together below in figure IV. xiv for comparison, separated by a 
cross-hatch along the x-axis. As the figure suggests background CM 
activity CMs collected after exposure to 104 ng/ml of LPS had twice the 
amount of IL-6 activity as assay and test background samples. LPS 
concentrations equal to or less than 103 ng/ml failed to induce any IL-6 
activity greater than relevant background samples. 
Figure IV.xiv. B-9 assay for IL-6 activity in CMs after exposure to different concentrations 
of LPS. The negative and positive controls for groups A, B, and C are included as 
indicated above. For groups D and E the negative control was 4 x 103 3H TdR cpm and the 
positive control ( 1.0 % T24 CM) was 60 x 103 3H TdR cpm. For each histogram, 
1=03% CM dilution, 2=.1% and 3=.3%. The x-axis is cross-hatched as described above 
to represent the inclusion of data from the second, comparable experiment. 

8 0 
TV. xv. TGF-B and LPS svner-.ze for IL-6 release from osteoblasts. Cells 
were cultured for 48 hours with LPS alone (at four concentrations), with 
TGF-B alone (at 10 ng/ml) or with both agents together. Data is presented 
in figure IV.xv and illustrate that LPS and TGF-B as single agents stimulate 
small or no release of IL-6 activity into CMs. Cells cultured with both 
TGF-6 and LPS, however, produced CMs with large increases in IL-6 
activity over background. The most striking increase in IL-6 production 
occured in the groups combining TGF-B and the lower LPS concentrations 
(10 and 100 ng/ml). These two groups of CMs had IL-6 activity similar to 
the groups combining TGF-B and higher LPS concentrations (103 and 104 
ng/ml). o , 
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Figure IV.xv. B-9 assay for IL-6 activity in CMs after exposure to different concentrations 
of LPS alone, TGF-B alone, and to both agents together for 48 hours. A negative 
experimental control is included. Negative assay control (B-9 cells alone) = 5 x 103 3H- 
TdR. Positive assay control (1% T24 CM) = 48 x 103 3H-TdR cpm. CMs tested at .3% 

IV.xvi. Release of IL-6 from osteoblasts is more dependent upon TGF-B 
than upon LPS. A series of 'priming' experiments were carried out as 
described in III. B, and similar to the experiments with GM-CSF in IV.v. 
Data from IV. xv suggested that for the induction of IL-6 activity, low 
dose LPS may interact with TGF-B as productively as higher dose LPS. 
The concentration of LPS used in IV.xvi was therefore lower than that 
used in experiment IV. xv in order to test the low concentration limit of 
LPS to synergize with TGF-B. 
TGF-B as the 'priming' agent: Data is presented below in figure 
IV.xvi and illustrates that cells exposed to TGF-B for hours 0-2 
manifested little enhancement of IL-6 activity in CMs. Similarly, LPS at 1 
pg/ml and 100 pg/ml for hours 2-48 also did not induce IL-6 release. 
However, cells first exposed to TGF-B for hours 0-2, washed and then 
exposed to 1 or 100 pg/ml of LPS for hours 2-48 produced CMs with high 
IL-6 activity. 
LPS as the 'priming' agent: Cells exposed to 1 pg/ml or 100 pg/ml of 
LPS for hours 0-2 did not produce CMs with increased IL-6 activity. 
Similarly, cells exposed to TGF-B for hours 2-48 also failed to show 
increases in IL-6 release. Cells exposed to 1 pg/ml of LPS, washed and 
then exposed to 10 ng/ml of TGF-B produced CMs with two- to three-fold 
the IL-6 activity of background samples. Cells exposed to 100 pg/ml of 
LPS, washed and exposed to 10 ng/ml of TGF-B produced CMs with higher 
IL-6 activity. 
The data in figure IX. xvi suggest (1) that cells can be 'primed' with 
TGF-B and activated by LPS for IL-6 release and (2) cells can also be 
'primed' by LPS, in a dose-dependent manner, for IL-6 release. These 

results are in contrast with the results of IV.v in which GM-CSF release 
was only obtained after cell 'priming' with TGF-B. LPS in IV.v failed to 
primed cells for GM-CSF release. 
3HTdR cpm x 10‘3 
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Figure IV.xvi. B-9 assay for IL-6 activity of CMs from cells 'primed' with either TGF-B 
or LPS, and then exposed to the corresponding synergen. Experimental controls are 
included. Negative and positive (1.0 % T24 CM) assay controls for this experiment were 7 
x 103 3H-TdR and 60 x 103 3H-TdR, respectively. CMs tested at .3 % dilution. 
B. STUDIES OF INTERLEUKIN-6: TGF-B and IL-1 
IV.xvii. Low-dose IL-1 alone does not induce IL-6 release but low-dose 
IL-1 svnergizes with TGF-B to induce a 12-fold increase in IL-6 release. 



















TGF-B on IL-1 activity, cells were cultured with either IL-1 alone (1, 10 
or 10 ng/ml) or with IL-1 and TGF-G (10 ng/ml). CMs were collected 
after 48 hours, and tested for IL-6 activity. As presented below in figure 
IV.xvii, low-dose (1 ng/ml) IL-1 did not induce IL-6 activity in tested 
CMs. However, 1-100 ng/ml IL-1 synergized with TGF-G to induce a 
large increase in the IL-6 activity of tested CMs. 
Figure IV.xvii. B-9 assay for IL-6 activity of CMs from cells cultured with either IL-1 
alone (1, 10 or 100 ng/ml), TGF-G alone (10 ng/ml) or with IL-1 and TGF-B together . 
Negative (0) and positive (+C: 1.0 % T24 CM ) assay controls are included as described in 
III.B and table IILi. Experimental background control (no agents) was 1 x 10^ T-dR 
cpm. All CMs tested at 0.3 % dilution. 
IV.xviii. IL-l/TGF-G synergy for IL-6 release is not affected by 
indomethacin exposure.. Prostaglandins are potent inducers of IL-6 release 

and may mediate at least part of IL-1 induced bone resorption. To 
determine whether prostaglandin production by cells derived from rat 
parietal bone played any role in the observations presented above the 
following experiment was conducted. Osteoblasts in vitro were exposed to 











Figure IV.xviii. B-9 assay for EL-6 activity in a series of cyclooxygenase inhibition 
experiments with indomethacin. Agents were added to cell cultures for the period of time as 
indicated. Relevant controls are included as indicated: Negative assay control= 0, positive 
asay control (1.0% T24 CM) =+C. CMs tested at 0.3 % dilution. 

either TGF-6 alone or to low-dose IL-1 alone or to both agents together. 
Additional cells were similarly cultured but with the addition of the non¬ 
steroidal antiinflammatory agent indomethacin, a potent inhibitor of 
prostaglandin production. As shown above in figure IV.xviii, there was no 
IL-6 activity in CMs from cells cultured with the IL-1 alone or with TGF- 
B alone. As expected, TGF-B and IL-1 synergized to increase IL-6 release 
>10 fold. The addition of indomethacin to the cultures did not change the 
IL-6 release response of the osteoblasts cultured with either IL-1 or TGF-B 
alone. There was a slight (<5%) increase in the IL-6 released by 
osteoblasts cultured with all three agents (IL-1, TGF-B, and indomethacin). 
IV.xix.a./b. Most of the TGF-B/svnergen-induced release of IL-6 occurs 
between hours 0-6. specifically, between hours 2.5 and 6. TGF-B/LPS 
and TGF-B/IL-1 induced large increases in IL-6 activity of CMs after 48 
hours of cell treatment, as described above in IV. xv, xvi and xvii. To 
decribe a more complete spectrum of activity, CMs were collected at 
hours 0, 6, 22, and 48 of TGF-B/synergen treatment and analyzed for IL-6 
activity as described in III. C 2. A second experiment collected CMs at 
hours 0, 1, 2.5, and 6 hours after TGF-B/synergen exposure. As shown 
below in figure IV.xix.a below, CMs at time zero (CMs collected before 
addition of agents to media) contained no detectable IL-6 activity compared 
to background samples. IL-1 alone failed to induce IL-6 activity at any 
time point. TGF-B alone induced no activity in IL-6 activity after 6 and 22 
hours of treatment but induced activity after 48 hours of treatment. 
TGF-B and IL-1 together, however, induced a large increase in IL-6 
activity at 6 hours with a 15% increase between hours 6 and 22. All 48 




Figure IV.xix.a. B-9 assay for IL-6 release over hours 0-6, 6-22, and 22-48 of exposure to 
TGF-B alone, LPS alone, IL-1 alone, TGF-B with LPS, or TGF-B with EL-1. Ordinate 
values are presented ^s the counts per minute of 3H-Thymidine incorporation by B-9 cells 
after culture with a given .3% CM sample. Abscissa! values are the length of time of CM 
exposure to a given agent or agents. Negative and positive (1.0 % T24 CM) assay controls 
were 5 x 103 3H-TdR cpm and 85 x 103 3H-TdR cpm, respectively. Negative 
experimental control at each time point was always less than 5 x 103 3H-TdR cpm. 
an additional 26 hours. It was therefore noteworthy that there was an 
apparent decrease in IL-6 activity in 48 hour CMs from 22 hour CMs, as 
presented in figure IV. xix a. This difference may not accurately reflect 
true changes in IL-6 quantity in 48 hour CMs. Unless there is an active 
degredation or binding of IL-6 molecules between 22 and 48 hours, it is 
assumed that at least an equal quantity of IL-6 remains at 48 hours and that 
the decrease in IL-6 activity at 48 hours is an assay artefact. 

LPS as a single agent induced a small increase in IL-6 activity in 6 
hour CMs, but the level of activity remained the same over the following 
42 hours. TGF-b and LPS together induced a large increase in IL-6 at 6 
hours with additional, smaller increases occurring up to 22 hours. As 
discussed above, 48 hour CMs from cells exposed to both TGF-8 and LPS 
apparently had less IL-6 activity than CMs from 22 hours. 
The second experiment concerning the time interval 0 to 6 hours 
showed that the largest increases in IL-6 activity was achieved between 
hours 2.5 and 6, as presented in figure IV.xix b below. There was no 
IV.xix.b. B-9 assay for IL-6 activtiy in .3% CMs collected at 0, 1, 2.5 and 6 hours after 
exposure to indicated agents, are devoid of IL-6 activity. IL-1, LPS and TGF-B as single 
agents fail to induce significant increases in DL-6 activity at the time points indicated. TGF- 
B/IL-1 and TGF-B/LPS induce comparably large increases in IL-6 activity only after 6 
hours of treatment. These data suggest that the greatest rate of IL-6 release by TGF-B and a 
given synergen occurs between 2.5 and 6 hours of treatment. Control=media alone, EL- 
1=10 ng/ml, LPS=1Q ng/ml, TGF-B=10 ng/ml. Negative assay control (assay cells alone) 
was 8000 ^HTdR cpm of activity and the positive control (T24) was 65000 ^HTdR cpm of 
activity. 

detectable IL-6 activity of the CMs between hours 0 and 2.5. As the data 
from IV.xix a/b suggest, the kinetics of TGF-B synergy with LPS for IL-6 
release is similar to the kinetics of TGF-B synergy with IL-1: Maximum 
release is obtained between hours 2.5 and 6 of treatment, with a large 
decrease in the rate cytokine release over hours 6 through 48. These 
kinetics, summarized below in IV.xx, are also similar to the kinetics of the 
above synergens for GM-CSF release (IV.vii and IV.xi) suggesting that the 
effects of TGF-B for cytokine release may be achieved through common 
pathways. 
IV,xx. The rate of IL-6 release is at a maximum between hours 0-6, a rate 
18-20 times higher than the rate of release between hours 6 & 22 and 
between 22 & 48. 
As presented in IV.xix.a. above, the largest increase in IL-6 release 
occurs between hours 0 and 6, while smaller increases occur over the 
subsequent 42 hours. These differences are presented in figure IV.xx 
below as the rates of change in IL-6 release, or Acpm/Atime. As 
illlustrated in figure IV. xx, TGF-B and LPS induce an increase in the rate 
of IL-6 release to a maximum between 0 and 6 hours of treatment . The 
rate of release over the next 16 hours drops 90-95% to levels comparable 
to background. Finally, the rate of IL-6 release over hours 22-48 remains 
unchanged from the 6-22 hour release rate and is essentially background. 
Data from figure IV.xix.b suggests that cytokine released between 0 and 
6 hours is released mostly between hours 2.5 and 6 suggesting that there is 
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Figure IV.xx. Rates of change in IL-6 release in cells exposed to TGF-B + LPS or TGF-B 
+ IL-1, or single agents, for different intervals of time. The rate of change was determined 
as described in III. E using the data presented in IY.xviii a. The incorporated radioactivity 
in B-9 cells induced by a given sample of CM is quantitated as counts per minute (cpm). 
The cpm value (Acpm) is divided by the time interval in which a given CM was produced 
(Atime), either 6 hours, 22 hours, or 48 hours. The ratio of the change in cpm value of a 
given CM to the dme difference between given CMs is presented as the rate of change 
(Acpm/Atime) in EL-6 release. 
C. STUDIES OF INTERLEUKIN-6: TGF-B and PTH 
IV.xxi. Parathyroid hormone (PTH) alone does not induce IL-6 release, 
but higher doses of PTH svnergize with TGF-B to induce a large increase 
in IL-6 release. Experiment IV.viii suggested that PTH had no clear 
effects on osteoblast release of GM-CSF. To determine the effect of PTH 
on IL-6 release and whether TGF-B could change the profile of PTH 

activity, cells were cultured with 0.02 to 20.0 nM PTH alone, TGF-B alone 
(0.4 nM or with both PTH and TGF-6 (0.4 nM). As described in III.C 2, 
CMs were collected after 48 hours incubation and assayed for IL-6 activity 
in the B-9 hybridoma assay. Data presented below in figure IV.xxi suggest 
that PTH alone does not induce IL-6 release. 2 or 20 nM PTH synergizes 
with TGF-B to induce an increase in IL-6 activity in tested CMs. Note that 
the effect of 2.0 nM PTH with TGF-B is largely additive for the induction 
of IL-6 release. 
Figure IV. xxi. B-9 assay for IL-6 activity of .3% CMs from cells cultured with either 2.0 
nM or 20 nM PTH alone, or with both PTH (.02, 0.2, 2.0 or 20 nM) and TGF-B (0.4 
nM). Negative experimental control (0) is included. Negative and positive (1.0 % T24 
CM) assay controls were 4 x 103 3H-TdR cpm and 45 x 103 3H-TdR cpm, respectively. 

IV. xxii. PTH/TGF-B synergy for IL-6 release may be TGF-B dependent. 
As described in III. B, a series of 'priming' experiments were done in 
which osteoblasts were exposed to TGF-B alone for two hours at a 
concentration of 400 pM. The cells were then washed, and then incubated 
with PTH (.20, 2.0 or 20 nM) for the next 46 hours. The converse 
experiment, namely PTH 'priming' followed by TGF-B exposure, was not 
performed. As shown below in figure IV.xxii, there was no IL-6 activity 
in CMs from cells cultured with TGF-B alone for hours 0-2, and then with 
fresh media alone for hours 2-48. However, cells incubated with TGF-B 
for hours 0-2 and then PTH for hours 2-48 produced CMs with the high 
IL-6 activity seen in previous experiments. 
3HTdR cpm x 10“3 
Figure IV.xxii. B-9 assay for EL-6 activity in a series of 'priming' experiments. Agents 
were added to cell cultures for the period of time as indicated. Experimental control is 
included. Negative and positive (1.0 % T24 CM) assay controls were 4 x 103 3H-TdR 
and 45 x 103 3H-TdR cpm, respectively. CMs asayed at a .3% dilution. 
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C. STUDIES OF M-CSF 
IV. xxiii. TGF-B does not stimulate the secretion of M-CSF. As described 
in III.B, osteoblasts were cultured in media alone or in media with TGF-B 
at three different concentrations, 0.1 ng/ml, 1.0 ng/ml or 10 ng/ml. CMs 
were collected and assayed for Macrophage-CSF (M-CSF) using the BAC 
M-CSF-dependent macrophage line. 
Figure xxiii. BAC cell assay for M-CSF activity of CMs from osteoblasts cultured with one 
of three concentrations of TGF-B: 100 pg/ml, 1.0 ng/ml, or 10 ng/ml. The abcissal values 
correspond to the counts per minute of incorporated tritiated thymidine by the BAC cells in 
the M-CSF assay. The ordinate values are indicated per diagram. Assay positive (10 % 
L929 CM) and negative controls are included while the experimental control (10 % media 
alone) value was 26 x 103 3H-TdR cpm. 
\ 
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As presented in figure IV.xxiii above, TGF-B at the concentrations tested 
did not induce any M-CSF release from osteoblasts detectable in the CMs 
IV.xxiv. TGF-B and LPS fail to svnergize for M-CSF release from 
osteoblasts. Osteoblasts were cultured with either TGF-B, LPS, or TGF-B 
and LPS together as described in section III. B. CMs were tested for M- 
CSF activity as outlined above and in table ffl.i. As presented in figure IV. 
xxiv below, 100 ng/ml LPS induced M-CSF activity in tested CMs as 
reported previously87. However, TGF-B had little or no effect on the 
osteoblast response to either dose of LPS for M-CSF release. 
Figure IV.xxiv. BAC cell assay for M-CSF showing relative amounts of activity of tested 
CMs. • =TGF-B at 10 ng/ml, ♦= LPS 10 ng/ml, 0= LPS 100 ng/ml,■= TGF-B at 10 
ng/ml + LPS at 10 ng/ml,D= TGF-B at 10 ng/ml + LPS at 100 ng/ml. The abcissal values 
correspond to the counts per minute of incorporated tritiated thymidine by the BAC cells in 
the M-CSF assay. The ordinate values are indicated as % CM tested. The negative and 
positive (10 % L929 CM) assay control values were 14 and 135 x 103 3H-TdR cpm, 
















D. BONE MARROW INDUCTION STUDIES 
IV. xxv. TGF-Beta and IL-1 do not induce the proliferation of total bone 
marrow cells from C3H/HeJ mice. As described in III. A, bone marrow 
cells were obtained from the long bones of C3H/HeJ mice. C3H-HeJ mice 
carry a recessive gene which renders them unable to respond to most forms 
of lipopolysaccharide (M. Horowitz, personal communication). C3H/HeJ 
cells were therefore selected to test any stimulatory effect of LPS on the 
assay cells described in IV.A-C and to test the effect of LPS and TGF-B 
on total marrow populations. Marrow cells were 
Figure IV.xxv. 12 hour incorporation of tritiated thymidine by C3H/HeJ marrow cells 
during exposure to CMs from experiment IV.xxiii. Ordinate values are indicated. 
Negative (0) and positive (+C:i929) assay control groups are indicated. 

9 5 
cultured with TGF-Beta (10 ng/ml), with LPS (10-1000 ng/ml) or with 
both agents together. As shown in figure IV.xxv above, the marrow cells 
exposed to both TGF-B and any concentration of LPS showed a small 
increase in proliferation over control groups as measured by uptake of 
tritiated thymidine. The additive effect of LPS and TGF-B for marrow cell 
proliferation is less the synergistic effects of LPS and TGF-B presented in 
previous sections. One may note, however, that the present experiment 
utilized total marrow populations and not specific assay cells (i.e. HT-2) 
responsive to a limited number of cytokines. The marrow population 
contains all cell types- the number of cells represented which are 
responsive to TGF-B/LPS-induced cytokines may be too small to mount an 
observably high increase in proliferation 
E. STUDIES WITH PLATELET-DERIVED GROWTH FACTOR 
IV. xxvi. PDGF and IL-1 svnergize to increase GM-CSF production. 
TGF-B may control the bimodal growth response of osteoblasts to 
the hormone via the autocrine elaboration of PDGF-AA, -AB, and/or -BB 
and the control of the PDGF receptor102,103# has been found to 
influence mitogenesis of fibroblasts and smooth muscle cells (SMCs) by an 
analogous induction of PDGF release. Osteoblasts are known secretors of 
PDGF-BB but express receptors for both PDGF-AA and PDGF-BB. It 
was hypothesized that the synergy between TGF-B and IL-1 for cytokine 
release may be due to an autocrine PDGF loop. To test the hypothesis, 
osteoblasts were cultured in media alone, with PDGF-AA, with PDGF-BB, 
with IL-1 or with IL-1 plus one of the two PDGF isoforms. CMs were 
assayed for GM-CSF activity. Data presented below in figure IV. xxvi 

show that IL-1 and PDGF-BB synergized to enhance GM-CSF release 
from osteoblasts but the effects of IL-1 and PDGF-AA was not as 
pronounced. 
% C M 
Figure IV. xxvi. HT-2 assay for GM-CSF activity: Effects of IL-1 and PDGF isoforms 
on the release of three cytolanes from osteoblasts. 0= assay control, 0=IL-1 10 ng/ml, 
A=PDGF-AA 10 ng/ml, [j]=PDGF-BB 10 ng/ml, #=IL-1 + PDGF-AA each 10 ng/ml, 
■=IL-1 + PDGF-BB each 10 ng/ml. Negative and positive (10% rh-IL-2) controls had 
values of 0.7 x 10-3 3H-TdR cpm and 95.0 x 10-3 3H-TdR cpm , respectively. CMs 
tested at .3% dilution. 

V. DISCUSSION Summary of findings; Possible 
mechanisms of TGF-B synergy and roles in bone remodeling and hematopoesis; 
Unifying concepts of TGF-B in cell biology; Future studies 
Normal bone remodeling is a dynamic process in which the 
concerted action of osteoblasts and osteoclasts can replace the entire 
human skeleton with new bone in less than three years. Normal 
bone formation requires the osteoblast to regulate its growth, to 
respond appropriately to extracellular signals and to function 
cooperatively among a population of other cells. Abnormal bone 
formation and bone disease is the result of defects in these processes. 
The complexity of normal bone formation and the difficulty of 
understanding the process of bone disease may be appreciated by the 
gross examination of pathologic specimens of bone. The following 
case of osteomyelitis from the American Civil War is particularly 
striking, as the severity of disease is seldom seen in today's world of 
antibiotics. 
On 15 June, 1865, Corporal Walter Ford of the 1st United 
States Colored Troops was wounded in the left leg by a 1/4 inch ball 
fired in an antebellum incident in Petersburg, Virginia. Taken to a 
Baltimore hospital, the 20 year-old Ford struggled with erysipelas, a 
recurrent wound infection and "continual pain"*. The corporal 
eventually died of "general fatty degeneration and leukocythaemia"* 
in February of 1866. Army surgeons had been collecting 
traumatized bone specimens throughout the war to medically 
categorize the spectrum of war injuries and so preserved Ford's left 
femur, now in permanent storage at the Army Medical Museum in 
Washington, D.C. As shown in figure V.i a below, the femur was 
*U.S. Army Surgeon's Report, 1882 
' 
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was fractured completely midshaft. An irregular bone callous joined 
the proximal ends with disorganised, abnormal bone occurring in 
areas far from the immediate trauma locus. In contrast, in figure 
Figure V.i.a. Left femur of Corporal Walter Ford, 1st United States Colored 
Troops, who sustained a "shot fracture" of the leg in June, 1865, suffered months 
with recurrent infections and eventually succumbed in February, 1866. The 
haphazard and irregular bone formation typical of osteomyelitic remodeling which 
produces a brittle, porous bone. Photograph courtesy of the Department of 
Defense, Armed Forces Institute of Pathology. 
V.i.b, is the normal bone formation of a similar fracture of the right 
femur from a Peruvian male dated circa 2000 B.C. Corporal Ford’s 
case is important in that it addresses aspects of bone biology essential 
to this thesis: First, what signals do osteoblasts use to form bone in a 
regulated, polarized fashion in normal or traumatic bone 
remodeling? Second, how can such signals be changed in an infected 

locus to produce distorted, haphazard bone? And third, are defects 
in these processes important in the development of bone diseases and 
cancer? A better understanding of these challenging issues may 
Figure V.i.b. Right femur of a Peruvian male, dated 2000 B.C. Fracture most 
likely the result of blunt injury or fall, suggesting the wound was closed and sterile. 
The presumably aseptic fracture has been healed by a regular, organized process of 
bone remodeling in marked contrast with that of figure V.i.a. Photograph courtesy 
of the Department of Defense, Armed Forces Institute of Pathology. 
come since the discovery of several unique endocrine properties of 
the normal osteoblast and its environ: 
It has been recently demonstrated that osteoblasts are among the 
body's most active producers of cytokines, a hormone class 
implicated in the control of hematopoesis and other growth 
processes. Osteoblast cytokine production has been studied for roles 
in bone metabolism and in fracture healing, but a definitive role for 
cytokines in bone remodeling is not yet clear29,87< 

100 
Transforming Growth Factor-Beta (TGF-B) is a platelet-derived 
hormone which is stored in the matrix of bone. TGF-B is a pleotropic 
protein whose actions range from immunosuppression to matrix 
upregulation167. This thesis presents experiments which studied the 
effects of TGF-B on osteoblast cytokine release in vitro. We present 
evidence that TGF-B has multiple effects upon osteoblast cytokine release 
which can be summarized below and in figure V.ii: 
(1) TGF-B induces IL-6 but not GM-CSF release 
from osteoblast in vitro. 
(2) Parathyroid hormone (PTH), and low dose 
lipopolysaccharide (LPS) and Interleukin-1 (IL-1) are 
not inducers of cytokine release from osteoblasts in 
vitro. 
(3) TGF-B synergizes with low dose LPS* or IL-1* 
to induce the secretion of both GM-CSF and IL-6 
from osteoblasts in vitro. 
(4) TGF-B synergizes with PTH* to induce the release 
of IL-6 from osteoblasts in vitro. 
(5) The enhanced cytokine production by TGF-B and 
a synergen is not ablated by indomethacin. 
(6) TGF-B functions to "prime" osteoblasts to respond 
to LPS and PTH. 
(7) The rate of cytokine release is at a maximum 
between 0 and 6 hours after exposure to TGF-B and a 
*Any molecule discussed in this thesis which synergizes with TGF-B for cytokine 
release will, for clarity, be referred to as a synergen. 
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synergen. The rate of cytokine release falls to baseline 
thereafter. 
(8) TGF-6 fails to upregulate the release of M-CSF 
from osteoblasts in vitro and does not enhance LPS- 
induced release of M-CSF. 
These experiments are the first to characterize a synergistic 
relationship between TGF-6 and other molecules to enhance 
cytokine release from bone cells. 
Furthermore, this is one of the first reports of an ability of 
TGF-6 to upregulate cytokine release from any cell type. The 
observations are unusual in that TGF-6 has previously been regarded 
as a negative growth regulator and as an immunosuppressive agent. 
Figure V.ii. Effects of TGF-6 and various synergens on osteoblast cytokine 
release. TGF-6 and PTH will synergize to induce the release of IL-6 from 
osteoblasts. TGF-6 can also synergize with either IL-1 or LPS to induce the release 
of IL-6 as well as GM-CSF. 
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Its ability, however, to upregulate fibroblast matrix formation and to 
induce neoplastic growth in normal fibroblasts underlies the 
pluripotent affects of TGF-B on cell biology. 
According to the data presented in this thesis, TGF-B confers 
upon osteoblasts the ability to respond to several unrelated molecules 
in a similar way with greatly upregulated cytokine release. The 
characteristics of each response, however, suggest that osteoblasts 
respond to TGF-B in a regulated, hormone-specific manner, and that 
the response is important to the cell as it is preserved even after 24 
hours of serum deprivation. These hypotheses are supported by data 
which are discussed separately in the following sections: Cell Purity, 
Cell Dormancy and Reactivation, Response Rapidity, Cytokine 
Specificity, TGF-B dependence, Mechanisms of Synergy, and New 
Elements of Bone Remodeling and Hematopoesis. 
Cell Purity. No method in the contemporary literature 
achieves cell cultures from bone which are 100% osteoblasts. The 
extraction procedure by Wong et al.208, however, produces 
osteoblast cultures with 95% purity as determined by analyses of 
specific protein marker profiles33*3. Wong et al. employed a 
collagenase digestion technique to isolate fetal osteoblasts and is the 
protocol used in this thesis. Known contaminating cells include 
fibroblasts and tissue macrophages. Fibroblasts are known 
producers of some cytokines. The fibroblast contribution to the 
magnitude of cytokine release observed in these experiments may be 
small, based on the actual number of such cells identified in 
osteoblast preparations33*3’208. Macrophages, however, despite low 

numbers, can secrete Interleukin-1, which may potently alter the 
osteoblast response to TGF-B. To test this possibility, all CMs 
assayed were analyzed for inherent Interleukin-1 activity as 
described in III. A and C using the LBRM assay. No significant IL-1 
activity was detected in any conditioned medium from cultured 
osteoblasts, regardless of the type of added stimulatory reagent (data 
not presented). The sensitivity of the LBRM assay allows a 
determination of IL-1 activity from concentrations as small as 10 
pg/ml (Horowitz, M., pers. comm, and Zltonik et al.213b). The 
cultures of osteoblasts used in these studies were, therefore, 
relatively pure. The cytokine activity of each tested CM was most 
likely derived from osteoblast activity and not from contaminating 
co-inhabitants of fetal rat parietal bone. 
Cell Dormancy and Reactivation. As discussed in section II. B, 
all osteoblasts cultured for these studies were serum-deprived in 
vitro for 24 hours in media alone prior to experimentation. Cells 
cannot grow in vitro in serum-deprived media, but will survive for 
periods of time. Normal cells respond to the serum-deprived state 
by shutting off cellular activities not essential towards the 
maintainence of basic cellular integrity. Serum-deprived cells leave 
the active cell cycle and enter the Go phase of cell life- a 
'housekeeping' period of dormancy in which there exists minimal 
energy expenditure, gene activity or protein production. Our 
observation that TGF-B induces cytokine release in such dormant 
cells suggests that the ability to produce and release cytokines is 
preferentially maintained in the Go osteoblast and that TGF-B may be 
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an important hormone for activation of this response in vivo. What 
remains to be determined is the importance of cytokines, and the 
rapid upregulation of cytokine production in the quiescent osteoblast. 
Response Rapidity. Preliminary experiments tested CMs from 
osteoblasts cultured with TGF-B and LPS after 48 hours of exposure. 
To obtain a more complete response curve, additional experiments 
analyzed CMs from osteoblasts after 1, 2, 6, 12 and 48 hours of 
exposure to TGF-B and LPS. As presented in figures IV.vi.a/b and 
xix a/b, data revealed that 95% of the GM-CSF and IL-6 activity 
found in the CMs after 48 hours of exposure was found in 6-hour 
CMs but not in 2.5-hour CMs. The relative rates of cytokine 
release over the five timepoints were determined as the ratio of the 
change in cytokine cell-proliferating activity (A CPM) to the change 
in time (At) and presented in figures IV. vii and xx. The rate of 
release for both GM-CSF and IL-6 is at a maximum from hours zero 
to six. From 6-22 hours, the release rate drops 75-90% and from 
22-48 hours, the rate returns to near baseline values. These results 
suggest that the effect achieved by TGF-B and a given synergen on 
GM-CSF or IL-6 release is rapid and short-lasting. How and why 
the osteoblast maintains secretory pathways to respond quickly after 
appropriate stimulus, even after 48 hours of serum-deprivation, is 
not clear. 
Cytokine Specificity Osteoblasts are known to secrete three 
cytokine hormones: two colony stimulating factors (M-CSF and 
GM-CSF) and Interleukin-6 (IL-6). All three molecules were tested 
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in CMs derived from stimulated osteoblasts. Only two of the three, 
GM-CSF and IL-6, were affected by TGF-B stimulation with a given 
synergen, either IL-1 of LPS. PTH was a unique synergen in that 
TGF-B/PTH elevated the release of IL-6 but did not change the 
release of GM-CSF (Figures V.ii). The release of the third 
osteoblast-derived cytokine, M-CSF, was not changed by the TGF- 
B/synergen combinations studied. The interchangeability of LPS 
and IL-1 as synergens for TGF-B stimulation suggest that LPS and 
IL-1 may utilize similar intracellular pathways of activation in 
concert with those utilized by TGF-B. PTH, however, may utilize 
still other pathways to specify release of IL-6. Several questions 
arise. First, how do the roles of the cytokines differ in the local 
environment when IL-6 is released singly (TGF-B + PTH) or in 
combination with GM-CSF (TGF-B + IL-1 or TGF-B + LPS)? 
Second, what is the significance of the exclusion of M-CSF from 
these reactions, besides the assumption that its release utilizes 
pathways unaffected by TGF-B. Would the release of M-CSF in 
addition to the other hematopoetic cytokines be a biologic 
redundancy or counteract the effects of these other molecules? The 
described roles of M-CSF in bone biology are limited but include a 
role as growth promoter for osteoclasts12813’206’212. GM-CSF and 
IL-6 may function to upregulate osteoblast activities which could be 
lessened by M-CSF-induced osteo clast activity. 
Dependence of Synergy on TGF-B A set of 'priming' 
experiments were conducted in which cells were exposed to TGF-B 
for two hours, washed, and exposed to LPS. Conversely, other cells 
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were exposed to LPS as the 'priming' agent, washed, and then 
exposed to TGF-B. Results from figures IV.v and xvi demonstrate 
that the increases in cytokine release previously observed were 
duplicated when cells were initially exposed to TGF-B and then to 
LPS. Little or no increase in cytokine release was seen when cells 
were first exposed to LPS and then to TGF-B. Cells could also be 
primed for IL-6 release by TGF-B with subsequent exposure to PTH 
(Figure IV. xxii). 
These observations suggest that the synergy between TGF-B 
and a given synergen for cytokine release may be dependent upon 
TGF-B itself. TGF-B may possibly function to prepare the osteoblast 
to respond to a secondary stimulus, such as LPS or PTH, with large 
releases of active cytokine. Studies with TGF-B as a cell primer for 
IL-1 are to be performed. Clearly, any effect that TGF-B imparts 
upon the cell lasts long enough to augment the stimulatory effect of a 
subsequent agent. What enables TGF-B to 'prime' the osteoblast for 
cytokine release is not clear. 
Mechanisms of Synergy. It is difficult to determine the roles 
of TGF-B in osteoblast stimulation and those of a given synergen but 
some assumptions may be made. First, activation of the cell by 
TGF-B may utilize pathways different than those of LPS or PTH 
since cells can be 'primed' by TGF-B and not by these two synergens. 
Second, activation of the TGF-B-mediated pathway(s) is the rate- 
limiting step in cytokine release since the process is TGF-B 
dependent. Third, the pathways utilized by TGF-B in enhancing 
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cytokine release must be readily activated, within hours of exposure, 
to high levels, even in the serum-deprived state. 
Three hypotheses arise which may unite the observations 
presented above concerning the role of TGF-B and its synergens in 
cytokine secretion: (1) TGF-B functions to upregulate the number 
or activity of surface receptors for a given synergen; (2) TGF-B 
functions to upregulate second messenger systems common to TGF- 
B and its synergens; and (3) TGF-B induces the release of Platelet- 
Derived Growth Factor (PDGF) which, in turn, activates the 
osteoblast in concert with another synergen. Each hypothesis is 
supported by data in the present work and data in the literature and 
will be briefly discussed as follows. 
a. Upregulation of synergen surface receptors by TGF-B. 
A qualitative analysis of osteoblast IL-1 receptor mRNA was 
performed in which cells were exposed to TGF-B, a synergen, and to 
both agents together. The results presented in figure IV. xii suggest 
that osteoblasts exposed to TGF-B have more mRNA for the surface 
receptor for Interleukin-1 (IL-1R) than control cells. The messsage 
level is unchanged by IL-1 itself. This is in contrast with the 
fibroblast studies by Dubois et al.54 who found that TGF-B 
suppressed fibroblast expression of IL-1R. Transcriptional studies 
will determine whether this affect is secondary to enhanced mRNA 
stabilization or to increased message synthesis. If TGF-B enhances 
expression of functional IL-1R, it remains unclear what pathways the 
IL-1R activates for cytokine release. The synergy between TGF-B 
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and IL-1 for GM-CSF release may, therefore, be a two-step process 
in which TGF-B first increases IL-1R levels allowing the cell to 
respond to a previously sub-stimulatory level of IL-1 (Figure 
V.iii.a). Increased osteoblast sensitivity to IL-1 may be particularly 
important for the cell's response to early infection when local IL-1 
levels are low. 
b. Upregulation of svnergen second messenger systems by 
TGF-B. 
TGF-6 may function to 'prime' cells by activating second 
messenger systems from quiescence or baseline state. The TGF-B 
receptor may act to upregulate proteins maintained in the quiescent 
state for the trans-activation of a broad range of regulated genes. 
Alternatively, TGF-B may simply enhance a rate-limiting step for 
second messenger production by a synergen102. 
Most growth factors induce the production of second 
messenger signals, like diacylglycerol (DAG) and intracellular 
calcium ([Ca+ + ]i), by enhancing phosphotidylinsoitol (PI) 
turnover168. Cells can be stimulated by agents which substitute for 
DAG and [Ca++]i, such as phorbol esters and calcium ionophores, 
resepectively138d50> pi turnover may not be the sole mechanism to 
achieve this end. Many primary cells require two growth factor 
signals- one that enhances PI turnover and one that does not168. T- 
cells, for example, proliferate maximally only after co-stimulation 
by antigen and IL-1. Antigen increases PI turnover but IL-1 does 
not. As presented in II. B, Rosoff et al. showed that IL-1 stimulates 
the production of another phospholipid, phosphotidylcholine 
(PC)168. PC hydrolysis produces a species of diacylglycerol (DAG) 
! , 
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distinct from DAGs produced after PI hydrolysis. As shown in 
figure II. ix, the two DAG species activate species-specific kinases 
which synergize to activate transcription factors. 
TGF-6 may prime osteoblasts to respond to IL-1 by enhancing 
IL-1- specific DAG production or DAG-dependent kinase activity 
from baseline state. This would allow the rapid up-regulation of 
second messenger systems while maintaining the specificity of IL-1- 
induced pathways. Alternatively, TGF-B may itself produce DAG- 
species which synergize with those derived after IL-1 stimulation for 
protein kinase C activation. 
The second messenger pathways important in LPS activation 
of the cell are not as well-characterized as IL-1, but most likely 
involve hydrolysis of the cyclic nucleotides, cAMP or cGMP“d,61 
TGF-B may function to upregulate the activity of the second 
messenger system by enhancing or activating distal enzymes such as 
protein kinase C or A or other LPS-specific serine kinases. 
The 'priming' of the cell by TGF-B, as discussed above, 
would correspond to the rapid activation by TGF-B of rate-limiting 
steps in second messenger systems. Subsequent ligand binding by a 
synergen would then utilize the activated second messenger system 
for full cell stimulation and cytokine production. Second messenger 
upregulation by TGF-B would provide for a rapid, efficient process 
of specific kinase activation without the need for transcriptive or 
translative processes. 
r. PDGF as a mediator of TGF-B/svnergen stimulation of 
osteoblasts. 
Workers have shown that a TGF-B-controlled autocrine loop 
exists involving Platelet-derived Growth Factor (PDGF)1°>95: Low 

levels of TGF-B upregulate PDGF-AA release from smooth muscle 
cells and high TGF-B levels downregulate PDGF-a receptors. The 
combined effect may explain in part the bimodal effect on cellular 
growth seen over a range of TGF-B concentrations in 
TGF-P 
Figure V.iii. Hypothetical activation sequences of TGF-B synergy with IL-1 for 
cytokine release, a) TGF-B ligand induces post-receptor events which upregulates 
cytoplasmic and/or nuclear events for cell priming. TGF-B-induced events lead to 
bi) upregulation of receptors for IL-1 and/or b2) production of PDGF. In the latter 
hypothesis depicted in figure b2, IL-1 synergizes with autocrine PDGF dimer. The 
result of either bi or b2 leads to c) cytokine release. Adapted from concept by 
Palumbo et al. (with permission)154. 
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fibroblasts, smooth muscle cells, chondrocytes, and osteoblasts34’167 
Like TGF-6, IL-1 -induced mitogenesis has also been found to 
involve autocrine production of PDGF-AA160 and modulated by 
TGF-6155. 
PDGF exists in isoform mixtures derived from the three 
possible combinations of hormone subunits, A and B: A A, AB, or 
BB. Isoform AA is a ligand for a-type PDGF receptors and 
isoforms AB and BB are ligands for 6-type receptors. The PDGF A 
chain is efficiently secreted and is a potent inducer of cytokine 
production in fibroblasts103’1!9. The B chain remains cell associated, 
has a 25-fold higher transforming ability for fibroblasts, and is the 
homolog of the v-sis oncogene product. Osteosarcoma cells 
translate both PDGF-A and -B mRNA (c-sis) into processed 
polypeptide whereas normal human and rat osteoblasts produce only 
PDGF-A A71,72,81, implicating PDGF-BB and v-sis in neoplastic 
bone cell growth. In bone cell studies, PDGF-BB enhances 
osteoblast chemotaxis190, DNA synthesis and replication36, collagen 
synthesis and bone formation34’159. PDGF-AA has lower activity in 
these studies than AB or BB isoforms. 
Centrella et al. have shown that osteoblast PDGF receptors 
preferentially bind PDGF-BB over -AA although osteoblasts 
produce mostly the PDGF-AA isoform37,38a# This phenomenon is 
most likely a consequence of PDGF receptor type expression by the 
osteoblast, type 6 > a. IL-1 a, however, can increase PDGF-AA 
binding to induce levels of mitogenesis equivalent to levels induced 
by PDGF-BB386. PDGF-AA action on osteoblasts may be thus 
controlled by other local factors. 

Released PDGF-AA induces the oligomerization of cell surface 
receptors for other PDGF ligands and the oligomerized receptors 
synergize for tyosine kinase activity!7**. Multiple post-receptor 
events are complex and involve a physical association with four other 
enzymes including phospholipase C gamma (PLC-y)115,122^ 
phosphatidyl inositol 3-phosphate kinase (PI-3pK)5, the serine- 
threonine kinase raf-l1^ and GTPase Activating Protein 
(GAP) 103. TGF-B and IL-1 may thus synergize by converging on 
common PDGF-signalling pathways upregulated by TGF-B priming 
and enhanced further by IL-1 activation. 
To identify a role of PDGF expression in the synergistic 
elaboration of cytokines by TGF-B and IL-1, osteoblasts were 
exposed to IL-1 and PDGF-AA or PDGF-BB with the appropriate 
controls. As presented in figure IV. xxiv, PDGF-BB synergized 
with IL-1 for GM-CSF release from osteoblasts. Production of IL- 
6 was not assayed. The effect of PDGF-AA with IL-1 was less than 
the effect of PDGF-BB. Experiments in which osteoblasts are 
exposed to both TGF-B and IL-1 but in the presence of antibody to 
the PDGF-BB ligand and/or receptor are to be performed. Such an 
experiment would be likely to determine the role of PDGF-BB in 
TGF-B mediated cytokine enhancement. 
Cytokine release induced by TGF-B and a synergen from 
previous experiments occurs within 6 hours. It is unclear how TGF- 
B induces PDGF release and how IL-1 and PDGF then induce 
cytokine release within a 6 hour time frame. 
Two distinct growth factor signals are often required for cell 
stimulation. Fibroblasts can be stimulated by PDGF, which enhances 
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phosphotidylinositol turnover, if the cells are also exposed to a 
growth factor which does not enhance PI turnover168. As discussed 
in V.vi.b, such a ’second molecule' may be IL-1. PDGF and IL-1 
may, therefore, synergize for cytokine release by activating two 
separate pathways of cell stimulation which converge upon a 
common point for cytokine production, i.e. a transcription factor. 
It remains to be determined if PDGF may be significant in 
mediating the synergy between TGF-B and LPS or between TGF-B 
and PTH. 
Common Themes of TGF-B Activity. The hypotheses discussed 
above and presented in figure V. iii suggest that TGF-B acts as an 
early signal for generalized activation of the dormant cell. As 
presented in figure V. iv, TGF-B may initially activate a cell from 
quiescence while the cell’s ultimate response is determined by the 
presence of other serum growth factors. TGF-B was originally 
described as a transforming growth factor with such a role, as 
discussed in II. A. TGF-B, isolated from neoplastic cells in vitro, 
was observed to facilitate the transition from Go to Gi in normal 
cells and eventually induced neoplastic growth in cells exposed to 
PDGF-BB, EGF, and IGF-191. In normal conditions, as in the 
osteoblast studied in this work, TGF-B may be one of a few 
extracellular molecules, present in semm, which maintains the cell in 
the activated state. The absence of TGF-B from the extracellular 
mileau could imply the absence of other nutrients as well. The 
absence of TGF-B allows the cell to become quiescent and conserve 
metabolism in periods of nutrient scarcity. The presence of TGF-B, 
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however, would enable the cell to respond to other signals for 
structural protein synthesis, mitosis, or cytokine release. 
Considering the rapidity of cytokine release from the dormant cell, it 
is unclear if cytokines are important only as paracrine growth 
factors, or are important as autocrines in the processes of cell 
reactivation. 
These hypotheses do not consider the source of released 
cytokine. Translational inhibition studies would quickly determine 
whether new cytokine is produced or stored cytokine is released 
following cell stimulation. The latter possibility seems unlikely 
unless cytokines are so significant to the cell that they are stored for 
long periods in the dormant cell, ready for release when the cell is 
appropriately stimulated. 
New Elements in Bone Remodeling and Hematopoesis. The 
role of TGF-B and its synergens in cytokine release by osteoblasts 
remains unclear. Perhaps, as implicated above, TGF-B functions as a 
cell 'activator', enhancing second messenger or receptor systems 
utilized by synergens (Figure V.iv). The roles for TGF-B and its 
synergens may elude scientific determination for some time, but the 
effect of these molecules is clear: greatly increased cytokine release. 
As suggested previously, such a response may be important to the 
newly resuscitated cell since cytokine release is maximally observed 
less than 6 hours after stimulation from quiescence. What remains 
is to determine how cytokine release is important to the osteoblast, 
and what roles released cytokines may play in normal growth 
processes. Possible clues are suggested with analysis of the anatomy 

and biology of bone remodeling. Osteoblasts, the bone-forming 
cells, are situated in close proximity to the osteoclasts, the bone- 
resorptive cells, and to osteoclast resorptive pits or lacunae. Situated 
close to these cells, and adjacent to and supported by the bone matrix 
Figure V.iv. Common role of TGF-B in cell activation. A common concept for 
TGF-B's roles in growth transformation, matrix formation, and cytokine release 
may be that TGF-B functions to induce changes in the Go cell. These intracellular 
changes alone are insufficient to induce protein release but act to 'prime' the cell to 
respond to a secondary growth signal. 
itself, lies the bone marrow. Given the observations presented in this 
thesis, a possible model arises concerning the role of TGF-B and its 
synergens in bone remodeling and hematopoesis itself: As depicted 
in figure V.v, osteoclasts resorb bone and release from the matrix 
inactive TGF-B, as described on paes 12-13. The protons used by the 
osteoclast to resorb bone accumulate in the pit, and this low pH, 
combined with osteoclast enzymes, activates latent TGF-B. The 
active TGF-B diffuses the short distance to the osteoblast and binds to 
the TGF-B receptor. Meanwhile, parathyroid hormone which has 
diffused into the remodeling locus, stimulates PTH receptors on the 
same osteoblast. The TGF-B and the PTH synergize to induce 
osteoblast production of Interleukin-6. The IL-6 diffuses back and 
may enhance osteoclast resorptive activity, or diffuse across the 

resorptive locus and enter the bone marrow to induce IL-6- 
dependent marrow lines (B-cells)64. 
Other models arise when osteomyelitis or a fracture locus is 
BONE MARROW 
Figure V.v. Model for osteoblast cytokine release at the resorption locus, as 
described below, for TGF-B and IL-1 synergy. 
superimposed upon normal remodeling. Active infections, for 
example, would provide IL-1 from recruited bone and blood 

macrophages. IL-1 would synergize with TGF-8 to release both 
GM-CSF as well as IL-6, an effect perhaps mediated by PDGF. The 
GM-CSF could diffuse into the marrow space and induce the growth 
of and act as a chemoattractant for neutrophilic and monocytic lines. 
These cells may migrate into the remodeling locus to focus and 
augment the processes of bone healing from infection or trauma. 
Gram-negative bacterial osteomyelitis would also provide LPS, the 
active component of endotoxin, providing another synergen for 
TGF-8 dependent cytokine release. Continuous stimulation of 
cytokine production by exogenous LPS and LPS-induced IL-1 
release may ablate local control and feedback mechanisms in 
cytokine-mediated bone remodeling. Haphazard osteoclast and 
osteoblast activity may give rise to bone with the classic 
characteristics of unchecked and untreated osteomyelitis as seen in in 
figure V.i. 
Bone fracture, however, with accompanying hemorrhage and 
clot, would provide many molecules of PDGF-AB and BB, which 
may mediate many of the effects of TGF-13 for GM-CSF and IL-6 
production. TGF-13-induced osteoblast activity may also lead to 
increased osteoid formation and bone repair 157. 
With several ways to provide GM-CSF and IL-6, TGF-8 and its 
synergens could enhance the healing changes required in 
osteomyelitic and fractured mineralized tissue. What arises from 
these models is an impression that the local environment of the bone 
remodeling locus is intimately regulated on the local level by 
processes initiated by TGF-8. Whether in the pathologic conditions 
of trauma or osteomyeltis, or in normal bone remodeling, TGF-8 

may be an important mediator between osteoclasts, osteoblasts, and 
cell lines of the bone marrow. 
1 1 8 
There is some evidence in the literature that supports the 
hypothesis that osteoblast-derived cytokines may be important in the 
support of normal hematopoetic processes in the bone marrow43’87. 
The evidence presented in this thesis suggests that TGF-B may be an 
important molecule in the normal control of such a relationship 
between the stromal cell of the bone matrix (osteoblasts) and stromal 
cells of the bone marrow (stem cells). 
Cytokines doubtless evolved in cells which were dependent upon 
other cells for survival. Paracrine hormone activity most likely 
existed long before the multi-organ relationships in endocrine 
activity since the first complex 'organisms' were most likely two- or 
three-celled. The multi-cellular construction of the body increases 
the importance of paracrine relationships since the diverse biological 
activites of each cell type may be intimately controlled on the local 
level. Osteoblasts are no different than other cells in that osteoblasts 
regulate normal growth and function by responding appropriately to 
extracellular signals. Cytokines may be important molecules in the 
paracrine orchestration of cellular activity and growth in a localized 
area. The evidence presented in this thesis further implicates 
cytokines and TGF-J3 in local control mechanisms. What remains to 
be determined is the significance of such activities in normal bone 
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